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Abstract
Binding of the protein tyrosine kinase p5 6 1ck to T-cell co-receptors CD4 and CD8X is
necessary for T-lymphocyte development and activation. Here we demonstrate that Zn2 + is
essential for complex formation. In an in vitro binding reaction, Zn2 + mediates p56lck
association with a GST fusion protein containing the cytosolic domains of CD4 or CD8U;
no other metals tested support binding. Treatment of preformed GST-CD4/p56lck dimers
with Zn2 + chelators results in dissociation of GST-CD4 from p561ck suggesting that Zn2 +
is contained within these complexes. Furthermore, we show that within live cells,
CD4/p561ck and CD8W/p561ck interactions occur in a zinc dependent fashion. Specifically,
pretreatment of the human T-cell Jurkat cell line with membrane-permeable zinc chelators
disrupts CD4/p561ck complexes, and treatment of COS cells co-expressing CD8c and
p561ck with such chelators likewise leads to dissociation of CD8o/p561ck complexes.
CD4/p561ck and CD8/p561ck represent the first examples of intracellular proteins that
require zinc as a bridge for heterodimerization.
The TGF-s mediate a diversity of biological responses through the binding of a
types I (TPRl) and II (TfRII) receptor. Specifically, these cytokines bring about the
formation of a signalling complex consisting of a TfRI and TIRII heterocomplex - most
likely a heterotetramer. (Gilboa et al., 1998; Henis et al., 1994; Moustakas et al., 1993;
Yamashita et al., 1994) However, it has been shown that pre-treatment of cells with DTT
abrogates functional recruitment of TPRI to TGF-3 1-bound TfRII rendering the resulting
complex unable to signal. (Cheifetz et al., 1990; Wells et al., in press) We further report
that similar pre-treatment blocks binding of both TPRI and TfRII to TGF-$2, a ligand
distinct from TGF- 1 in that it requires co-expression of both receptors to bind. To identify
the properties of DTT required to elicit this phenomenon, we screened a number of
chemically related reducing agents for a similar inhibitory effect upon complex formation.
Here, we find that 2,3 DMP (2,3 dimercaptopropanol) likewise blocks functional
interactions between TPRI and TPRII. Both it and DTT are di-thiol based compounds that
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are membrane-permeable. Other thiol-containing compounds lacking either one of these
properties exert no effect on complex formation. In addition, DTT does not affect TPRI
homodimerization, an upstream event required for TPRIeTPRII hetero-oligomerization.
Hence, this would suggest that mechanistically, DTT and similarly, 2,3 DMP, act upon
intracellular factor(s) and through chemical properties related to the presence of di-thiols,
inhibit TPRIeTPRII association. The cytoplasmic domain of TPRI plays a critical role in
these interactions as we find that a cytoplasmically truncated T3RI fails to associate with
ligand-bound TPRII. In contrast, the TPRII cytoplasmic domain is dispensable for
complex formation, nor is it required to manifest the DTT effect. Therefore, we propose
that DTT directly abrogates functional TIRI-TPRII interactions by acting upon structural
elements lying within TfRI's intracellular domain that are necessary for it to be recruited by
TPRII.
It is thought that DTT, by reducing critical disulfide bonds in the extracellular
domain of TfR1, alters the receptor's conformation ultimately preventing TGF-P
binding.(Vivien and Wrana, 1995) Other membrane permeable dithiols exerted the same
effect. Because in contrast to monothiols, dithiols are metal chelators, we thought it
possible that chelation rather than disulfide bond reduction explained their findings. Hence,
our model predicts that Zn2 + is essential for the cytoplasmic domain of the type I receptor
to assume a particular conformation necessary for interactions with the II receptor. We test
this model by examining a number of predictions it makes regarding the structural nature of
the type I receptor. First, it predicts that the type I receptor cytosolic domain should bind
Zn2 + and its removal by pre-treatment with membrane permeable Zn2 + chelators should
block formation of a TGF- 1/types I and II receptor complex. Furthermore, mutations
resulting in the loss of zinc binding by the type I receptor should cause loss of recruitment
to the ligand bound type II receptor complex and therefore render it unable to signal. Our
experimental data however are only consistent with a subset of these predictions.
Therefore, our conclusions ultimately do not support an essential role for a divalent metal,
namely zinc, in formation of the TGF-P receptor complex.
Thesis advisor: Dr. Harvey F. Lodish, Professor of Biology
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Chapter 1
Literature review:
(1) Role of zinc in protein-protein interactions
(2) CD4/CD8 mediated T-cell activation
(3) TGF-P receptor signal transduction
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This thesis discusses two as of yet largely unstudied problems in protein/protein
interactions. First we characterize a novel role for zinc in the mediation of protein-protein
interactions. In particular, we examine the role of zinc in bridging the cytoplasmic domain
of T-cell co-receptors, CD4 and CD8c, to the lymphocyte specific tyrosine kinase, p561ck.
Secondly, we are interested in the process in which transmembrane proteins recognize and
ultimately associate with each other to form larger order complexes. Specifically, with
respect to the formation of the TGF-P signaling receptor complex, it has been demonstrated
that the types I and II TGF-$ receptors homodimerize in the absence of ligand and upon
ligand binding, form a types I and II heterotetramer. (Gilboa et al., 1998; Henis et al.,
1994; Moustakas et al., 1993; Yamashita et al., 1994) In this thesis, we examine the
structural determinants necessary for their oligomerization as well as DTT's mode of action
in blocking their formation. This introductory chapter discusses the biochemistry and
physiology of zinc and then reviews current models of CD4/CD8 mediated T-cell activation
and TGF- receptor signal transduction.
Zinc
Man's use of metals such as copper and iron for medicine and tool-making have
long been recognized as critical to the rise of human civilization. Copper for example was
discovered in - 9000BC and became widely used by the Greeks as medication for disease
as well as nearly all types of tools and jewelry.(Pena et al., 1998) In contrast, the
identification and importance of zinc emerged much later. In the production of metal works
for example, there is no evidence of zinc being intentionally used prior to the Pax Romana.
Indeed, ranking as one of their greatest achievements in metallurgy, the Romans introduced
large scale production of brass through the use of calamine (zinc carbonate); this
represented zinc's first use as a component for metal production.(Aitchison,
1960)However, elemental zinc remained unknown for at least another thousand years.
Because of its low boiling temperature relative to other metals (927TC), it easily vaporized
during the smelting process, and hence remained obscure to early metallurgists. It was not
until the Chinese developed a method in the thirteenth century to rapidly condense zinc
vapour (ZnO) to its liquid state that elemental zinc was first produced. Remarkably, during
the Chinese Ming Dynasty (1368-1644), the process became refined enough to produce
coins containing over 98% zinc.(Aitchison, 1960; Tylecote, 1992) During the proceeding
400 years, Europeans imported zinc from the Far East for producing brass. In fact, their
dependence upon Asian imported zinc did not end until 1738 when the Englishman William
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Champion patented a smelting method for producing metallic zinc.(Aitchison, 1960;
Tylecote, 1987)
Biochemistry of zinc
Zinc was first characterized as an essential element for plants just over a century
ago.(Raulin, 1869) Its role in biochemistry was first recognized in 1940 when Keilin and
co-workers purified carbonic anhydrase and showed that the presence of zinc was
necessary for catalytic activity.(Keilin and Mann, 1940) In the subsequent 50 years, zinc
has emerged as the most ubiquitous metal of the transition group IIB elements in biological
systems. Within proteins, it is able to assume a diversity of structural configurations
allowing it to play roles in both structural and enzymatic biochemistry. For example, zinc
metalloenzymes can be found in all six classes of enzymes established by the International
Union of Biochemistry. Secondly, in a structural role, Zn 2 + serves as the predominant
metal ion stabilizing cross-links within proteins. In fact, it has been estimated that
approximately 0.5 - 1% of all human cDNAs encode proteins containing zinc finger motifs,
a subset of all zinc binding domains.(Hoovers et al., 1992)
Two intrinsic properties of Zn2 + make it uniquely suitable for the tasks nature
assigns to it. First, like many group IIB metals, zinc has an oxidation state of +2
corresponding to the removal of two electrons from their least stable 4s orbitals. Based on
hard-soft acid base theory, this positive charge lends it Lewis acid properties. And for
Zn2 + in particular, the positive charge yields a borderline Lewis acid capable of ligating a
diversity of electron donors including oxygen, nitrogen and sulfur. Secondly, by virtue of
its filled d-shell orbital, it is electronically inert and as a result redox stable. In contrast to
other divalent metals such as copper and iron, no other oxidation states exist other than +2.
Consequently, zinc is uniquely suited to stabilizing cross-links within protein domains
without introducing undesired chemical reactivity.
Hence, zinc's versatility arises from two seemingly opposing properties: 1) flexible
Lewis acid properties and 2) its high redox stability. In fact, it is the nature of the binding
site constructed around the zinc ion that determines which of these two properties becomes
manifest. When fulfilling a structural role, zinc is always fully coordinated in a tetrahedral
configuration. On the other hand, with an open coordination site ligated to a water
molecule, zinc's Lewis acid properties are brought to bear upon enzymatic catalysis.(Vallee
and Auld, 1990) For example, in enzymes such as carbonic anhydrase and
carboxypeptidase A, it is believed that zinc can lower the pKa of the bound water molecule
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hence facilitating formation of a metal-bound hydroxide ion. The resulting hydroxide ion is
then capable of nucleophilic attack on a substrate molecule. In other enzymes such as
alcohol dehydrogenase, substrate displaces the zinc-bound water. Then zinc, as a Lewis
acid, polarizes the substrate molecule thereby priming it for nucleophilic attack. The identity
of the other three zinc bound ligands and their spacing appears to determine which
mechanistic pathway is used. Indeed, enzymes utilizing zinc to stabilize a metal bound
hydroxide ion lack coordinating cysteines and are generally characterized by at least two
histidine ligands. In contrast, most zinc alcohol dehydrogenases are characterized by a
single histidine and two cysteine ligands. This particular configuration may alter the bound
Zn2 +'s Lewis acid properties and consequently determine the pathway utilized.
Types of zinc binding domains
Zinc serves as a template around which proteins can form defined tertiary
structures. In general, energetic considerations dictate that polypeptides be of at least 50
residues in order to form stable tertiary domains.(Creighton, 1993) However, by using
zinc as a cross-link, polypeptides as short as 15 residues are able to fold stably. Nature has
put these domains to use in a wide diversity of functions including protein-protein, DNA,
RNA and DNA/RNA hybrid binding. In many cases, they participate in the sequence
specific binding of nucleic acids as illustrated by the enormous family of zinc finger
binding proteins. Numerous transcription factors contain zinc fingers that extend into the
major groove of the double helix where residues within the zinc finger interact with DNA
bases and backbone phosphates groups.(Pavletich and Pabo, 1991) Each zinc finger can
bind 3 contiguous bases of DNA.(Pavletich and Pabo, 1991) Greater sequence specificity
is achieved by simply assembling multiple zinc fingers each independently binding their
cognate DNA target sequence.(Desjarlais and Berg, 1992; Desjarlais and Berg, 1992)
Aside from their almost exclusive use of cysteines and histidines as coordinating
residues, the families of zinc binding domains are structurally diverse. The topologies of
the zinc ion ligands is a clear illustration of this structural diversity. Among zinc finger
domains, three proteins represent the configurations found in nature thus far. In the
primary sequence of the transcription factor TFIIIA, a single zinc ion is coordinated by a
pair of cysteines followed by a loop region and a second pair of histidines.(Miller et al.,
1985) Variations on this theme include steroid receptors and LIM domains characterized by
two zinc finger domains placed successively in close proximity to each other with the first
through fourth coordinating residues binding the first zinc ion and the fifth through eighth
binding the second.(Evans, 1988) In a more complex scheme, RING domains also possess
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two zinc binding sites ligated by eight residues. However, the two modules are not
discrete, and instead overlap each other.(Barlow et al., 1994; Borden et al., 1995;
Freemont, 1993; Saurin et al., 1996) Specifically, the first and third pairs of cysteines
coordinate one zinc ion and the intervening second and fourth pairs coordinate a second
zinc ion. Third, the transcription activator GAL4, by virtue of having two cysteines each
ligating two zinc ions, contains only six residues to coordinate two zinc ions.(Marmorstein
et al., 1992)
With respect to function, LIM and RING domains appear to be zinc binding
structures specialized for protein/protein interactions. RING domain proteins constitute a
family of proteins containing conserved pairs of zinc ligands; however their intervening
sequences and spacing are highly variable perhaps reflecting the myriad functions assumed
by RING domain proteins. This family of proteins are involved with cell cycle, signal
transduction, and viral pathogenesis. Unlike other zinc binding motifs, RING finger
proteins appear to be monomeric and hence may not able homo-oligomerize in the absence
of other factors. LIM domain proteins are less well characterized biochemically.(Dawid et
al., 1998) Many are found in homeodomain proteins and cytoskeletal proteins. Partner
proteins include other LIM proteins as well as a variety of other structural motifs.(Jurata
and Gill, 1998) While their structures suggest that they may be able to bind DNA, any
function in transcription has yet to shown.
Zinc as a protein-protein bridge
Although the paradigm of zinc binding domains forming structures involved in
protein-protein interactions has been well established, evidence of zinc directly bridging
two proteins has just begun to emerge. In such a role, the interacting interface would
possess a zinc binding site containing coordinating residues from each monomer. The HIV
Tat protein is a case in point.(Frankel et al., 1988; Frankel et al., 1988) Specifically, Tat in
vitro can form homodimers bridged by zinc. Biophysical measurements suggest the
presence of four zinc ions per dimer. Each monomer contains a cysteine rich domain highly
reminiscent in sequence to that of the metal binding sites in metallothionein. In addition,
presence of zinc appears to induce structural changes in this cysteine rich region presenting
further indication of this region's involvement with metal binding. Overall global folding
however appears to be unaffected. In another example, Wells and co-workers show that
human growth hormone binds human prolactin receptor with relatively low affinity.
However, in the presence of 50gM Zn 2 +, binding affinity increases by -8000
fold.(Cunningham et al., 1990; Cunningham and Wells, 1991) X-ray crystallographic data
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reveals a single zinc ion bridging prolactin receptor residues Asp 217 and His 218 to
growth hormone residues His 18 and Glu 174 deep in the binding interface. (Somers et al.,
1994) Although the physiological relevance of growth hormone binding the prolactin
receptor has yet to be established, this work nevertheless raises the possibility of
engineering interfacial zinc binding interfaces to enhance the affinity of protein-protein
interactions. In fact, Wells and co-workers, based on sequence alignment and
crystallographic data, deduced the corresponding residue in the growth hormone receptor to
a zinc coordinating residue in prolactin receptor, His218. Mutation of this specific residue
to histidine led to a mutant growth hormone receptor exhibiting similar zinc dependent
enhancement (20 fold increase) in ligand binding, lending credence to the feasibilty of such
an approach to protein engineering. (Matthews and Wells, 1994)
Zinc physiology
An average adult human contains 2 to 3 grams of zinc, making it one of the most
abundant physiological "trace" elements. Furthermore, largely attributed to its lack of
chemical reactivity as well as its apparently efficient physiological homeostasis, no known
human disorders have been associated with zinc toxicity. Additional evidence pointing to
efficient zinc homeostasis has come from studies of the effects of zinc deficiency.(Golub et
al., 1995; Golub et al., 1986) Symptoms of moderate zinc deficiency include hypogeusia
and a suppressed immune function, and with more severe deficits, anemia and anorexia.
However, very low levels of zinc intake are required to manifest these symptoms and as a
result, occurrences of such deficiencies are rare. In mice, even the most extreme of dietary
regimens induce only transiently decreased levels of zinc in tissues such as the brain. The
mechanisms of homeostasis remain unknown. Several putative zinc transporters have been
cloned. However, at this time, none have been directly demonstrated to facilitate zinc
transport. Total cellular and serum concentrations of zinc are in the 10-lOOiM
range.(Falchuk et al., 1995; Hocke et al., 1995; Nomizu et al., 1993; Reyes, 1996;
Swanson and Sharp, 1992; Tiran et al., 1993; Whitehouse et al., 1982) However, most of
it is bound to proteins. On the other hand, the free concentration of zinc is reported to be in
the picomolar range.(Maret and Vallee, 1996) Under such concentrations, many zinc
binding proteins, given their observed affinities for zinc, would incorporate very little of
the metal in their structure thus raising the question of how zinc becomes incorporated into
proteins. Recently, Vallee and co-workers have proposed that metallothioneins take on the
role of zinc storage and its transfer from one protein to another.(Fischer and Davie, 1998;
Jacob et al., 1998; Jiang et al., 1998; Maret and Vallee, 1998) Metallothioneins comprise a
family of proteins that bind zinc with extremely high affinity ( Kd - 10- 13 M) and high
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stochiometry (up to 7 zinc atoms/molecule). Their model rests on a key observation.
Specifically, because of metallothionein's relatively low redox potential (<-366mV), its
sulfur ligands can be readily oxidized by mild cellular oxidants such as oxidized glutathione
(GSSG) and protein disulfide isomerase.(Maret and Vallee, 1998) Such an oxidation state
would destabilize the zinc bound complex, causing its release and presumed transfer to
another protein. Therefore, zinc release from metallothionein and its subsequent transfer to
another zinc acceptor would be governed by the ratio of reduced to oxidized disulfides. A
high reduced/oxidized ratio maintains MT's high affinity for zinc whereas a low one would
cause oxidation of MT's sulfur ligands therefore favoring release of bound zinc.
Furthermore, their data suggests that this reaction is not strictly reversible suggesting
additional factors of regulation.
CD4 and CD8-mediated T-lymphocyte activation
T-cell activation
T-cell activation is the process by which a mature T-lymphocyte responds to the
presence of an antigen. The changes induced in the T-cell are determined by the
developmental history of the cell as well as the nature of the antigen. In particular, these
responses include proliferation, programmed cell death, growth factor production, cell
migration, cell-cell contact, and an ill-defined process called "memory." (Crabtree and
Clipstone, 1994)
Elucidation of CD4 and CD8 function
The development of two technologies in the 1970's, namely monoclonal antibodies
and fluorescence activated cell-sorting (FACS), dramatically accelerated efforts aimed at
understanding T-lymphocyte biology. Used in concert, they led to the isolation and
characterization of T-cell sub-populations based on their expression of a number of cell
surface markers. Shortly thereafter, it became evident that these markers could be correlated
with a T-lymphocyte's state of differentiation and function.(Reinherz and Schlossman,
1980) Among mature T-cells in particular, two sub-populations of cells exist, each
characterized by exclusive expression of a specific membrane glycoprotein: T-helper cells
are CD4 positive and T-killer cells are CD8 positive. Because blocking antibodies against
CD4 and CD8 could inhibit a variety of functions related to antigen recognition and
stimulation, it was clear that they played an essential role in T-cell function.(Dialynas et al.,
1983; Haskins et al., 1984; Haskins et al., 1983; Marrack et al., 1983; Marrack et al.,
1983; Swain et al., 1984; Wilde et al., 1983) Among such studies, S. Swain provided
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evidence suggesting that they interact with specific classes of MHC proteins.(Swain, 1981)
She observed that CD8 blocking antibodies inhibited functions specific for the class I major
histocompatibility complex (MHC), but had no such effect on class II MHC mediated
responses. Similar studies demonstrated CD4 involvement with class II MHC specific
functions. Beyond antigen stimulated T-cell activation, these MHC interactions also bear
implications in T-cell development as mice homozygously deficient for either glycoprotein
exhibit specific deficiencies in the maturation of their respective lineage specific T-
cells.(Fung-Leung et al., 1991; Rahemtulla et al., 1991)
Work extending the details of these interactions culminated in the demonstration of
physical association betweeen CD4 and class 2 MHC protein by Doyle and co-
workers.(Doyle and Strominger, 1987) These results led to the model proposing that CD4
and CD8 act as accessory molecules that increase adhesion between T-cell and APC. It
implies that such an accessory molecule and TCR would bind independently to different
MHC molecules and as a result increase cell-cell adhesion. CD4 and CD8 then presumably
allows the TCR to respond to lower levels of antigen. However, the "accessory molecule"
hypothesis fails to explain the strict association of CD4 and CD8 to their respective MHC
classes. Indeed, most professional APCs express both classes of MHCs and consequently,
either CD4 or CD8 binding to their respective MHCs should fulfil the cell adhesion
requirement for T-cell activation. Given that the model limits their roles to cell-cell
adhesion, strict segregation of CD4 and CD8 to specific MHC classes would not be
necessary.
In 1989, Janeway and co-workers propose an alternative model referred to as the
"co-receptor hypothesis."(Janeway, 1991; Janeway, 1992) In contrast to the "accessory
molecule hypothesis," they propose that in addition to an adhesion function, these
glycoproteins constitute required components of TCR-mediated signal transduction.
Janeway and co-workers also predict that upon antigen stimulation, CD4 and CD8 must
associate with TCR and bind the same MHC ligand resulting in a complex competent to
initiate T-cell signal transduction. Shortly thereafter, physical association between CD4 and
TCR was demonstrated providing the first evidence lending credence to the co-receptor
model.(Dianzani et al., 1992; Dianzani et al., 1992; Kupfer and Singer, 1988; Kupfer et
al., 1987; Kupfer et al., 1987)
Additional evidence of a signalling role emerged from the discovery that the
cytosolic domains of both CD4 and CD8x (a subunit of the CD8 complex) associate with
the non-receptor tyrosine kinase, Lck (p561ck).(Rudd et al., 1988; Veillette et al., 1988)
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Particularly, T-cells expressing CD4 intracellular truncations that do not bind Lck show
significantly reduced responses to antigen stimulation.(Miceli and Parnes, 1991; Miceli et
al., 1991) Under these circumstances, CD4 is incapable of placing Lck within close
proximity of the TCR thus abrogating any co-receptor mediated signal transduction.
However, in contrast to mice lacking CD4 or CD8c, transgenic mice expressing truncated
forms of CD4 and CD8x do not display complete impairment in T-cell development.(Fung-
Leung et al., 1993; Fung-Leung et al., 1991; Killeen and Littman, 1993; Rahemtulla et al.,
1991) This residual response in the organism would suggest the existence of Lck-
independent functions for CD4 and CD8, namely cell-cell adhesion. And indeed, ensuing
models of co-receptor function incorporate Lck mediated signal transduction as well as
MHC binding as factors essential for full T-cell activation.
Structural make-up of CD4 and CD8
While both co-receptors have similar functions, they are structurally different. CD4
is a single transmembrane glycoprotein possessing an extracellular domain folded into four
immunoglobulin-like domains, followed by a transmembrane domain and a 38 residue
cytoplasmic tail.(Maddon et al., 1985; Wu et al., 1997) Most studies are consistent with
CD4 being a monomer on the surface of cells. Under conditions optimized for
crystallization however, CD4 can form dimers.(Wu et al., 1997) Recent observations
suggest that TCRs can also dimerize raising the possibility of forming a heterotetramer
upon binding MHC.(Reich et al., 1997) In such cases, CD4 dimers may be
formed.(Vignali et al., 1996) However, whether these structures bear any relevance to
signal transduction in T-cells has yet to be determined.
CD4 is also a receptor for HIV. A number of reviews detail its role in
infection.(Baltimore, 1995; Chan and Kim, 1998; Choe et al., 1998; Finzi and Silliciano,
1998; James et al., 1996; McCune, 1991; McMichael, 1998)
CD8, on the other hand, exists as a di-sulfide linked dimer.(Norment and Littman,
1988; Snow and Terhorst, 1983) Although homodimers containing two a chains can form,
the major dimeric species expressed in mature T-cells consists of an a and P chain
heterodimer. Both chains are single transmembrane proteins characterized by an
extracellular domain containing a single immunoglobulin-like domain.(Kavathas et al.,
1984; Littman et al., 1985; Norment and Littman, 1988) CD8c is clearly required for CD8-
mediated signal transduction as it is the only subunit that interacts with Lck.(Rudd et al.,
1988; Veillette et al., 1988) The role of CD8, on other hand, is not entirely clear. Physical
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measurements indicate that it exhibits a faster 'on' rate of MHC binding than CD8u.(Garcia
et al., 1996) Hence it is thought that CD83 contributes to the stability of the MHC-
peptide/TCR complex and in fact, this increased stability correlates with the cX/
heterodimer more efficiently responding to antigen stimulation than the a chain
homodimer.(Renard et al., 1996)
Association of Lck with CD4 and CD8x requires two conserved cysteine residues
in the cytosolic domain of either co-receptor and two in the amino-terminus of lck.(Turner
et al., 1990) In particular, both CD4 and CD8x contain a CXCP motif. These cysteines
and their spacing within each domain are highly conserved, yet mutation of adjacent
residues has no effect on their association. In CD4, mutation of anyone of these two
cysteines results in failure to form a complex with Lck. In contrast, only the mutation of
both conserved cysteines in CD8x entirely abolishes its interactions with Lck.
Lck protein tyrosine kinase
Lck was first isolated as a membrane-associated phosphoprotein expressed at high
levels in a Moloney Murine Leukemia Virus transformed T-cell lymphoma
(LSTRA).(Casnellie et al., 1983; Casnellie et al., 1982; Gacon et al., 1982) It is expressed
in all immature and mature T-cell types.(Marth et al., 1985) Other cell types expressing Lck
include natural killer cells and activated B-cells.(Einspahr et al., 1990; Taieb et al., 1993)
Lck-deficient mice exhibit severe thymic atrophy accompanied by an almost total lack of
peripheral T-cells.(Molina et al., 1992) Such profound defects underscore its essential role
in thymocyte development. In addition, this phenotype is markedly broader in scope than
the phenotype caused by the combined disruption of both CD4 and CD8u. Together with
the finding that Lck also associates with the IL-2 receptor P chain, it is likely that Lck
possesses functions in T-cell development that are co-receptor-independent.(Hatakeyama et
al., 1991)
Lck is a member of the Src family of protein tyrosine kinases. And as such, it bears
a number of stereotypical stuctural features: (1) A myristylated N-terminal domain required
for association to the inner aspect of the plasma membrane; (2) an SH3 motif that binds
proline-rich peptides; (3) an SH2 motif that binds phosphotyrosine containing peptides; (4)
a catalytic tyrosine kinase region; (5) a negative regulatory COOH domain.
However, as mentioned previously, the Lck N-terminal domain is required for
association with CD4 and CD8c.(Shaw et al., 1989; Shaw et al., 1990; Turner et al.,
1990) Specifically, it possesses two highly conserved cysteines spaced as a CXXC motif,
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a feature unique to Lck. Mutation of either cysteine abrogates co-receptor binding.
Moreover, although wildtype Src kinase is unable to interact with either co-receptor, a
chimeric kinase tagged with only the unique Lck N-terminal domain does. Therefore, this
domain is both required and sufficient to mediate CD4 and CD8 association.
Lck activity is regulated by the opposing actions of the p5ocsk kinase and the CD45
phosphatase.(Bergman et al., 1992; Gervais et al., 1993; Koretzky et al., 1990; Nada et
al., 1991; Okada et al., 1991; Pingel and Thomas, 1989; Volarevic et al., 1992; Weaver et
al., 1991) Their equilibrium ultimately determines the phosphorylation state of tyrosine 505
located in Lck's negative regulatory COOH domain. While it is phosphorylated, the kinase
is inactive. In mechanistic terms, it is believed that the SH2 domain binds intramolecularly
to the C-terminal phosphotyrosine 505 thereby rendering the kinase domain closed to
external substrates. Indeed, deletion of either the SH2 domain or tyrosine 505 results in the
loss of repression and as a consequence, constitutive kinase activity.(Amrein et al., 1993;
Marth et al., 1988; Reynolds et al., 1992; Veillette et al., 1992)
A model has been proposed to describe the molecular details of Lck involvement in
T-cell signal transduction. First, by virtue of associating with CD4 and CD8, antigen
stimulation places it within close proximity of the TCR. This in turn leads to CD45-
mediated desphosphorylation and hence activation of Lck. In concert with Fyn, another src
kinase, Lck is believed to then phosphorylate a number of TCR subunits including the TCR
( chain and the CD3 y, 8, and F chains.(Mustelin et al., 1990; Qian et al., 1993; Samelson
et al., 1986; Straus and Weiss, 1993; Weiss, 1993) This rapid generation of
phosphotyrosines is believed to provide a scaffolding to bind a large array of SH2-
containing molecules required for the first step of signal amplication including downstream
effectors such as Zap70, PLCy, Vav, and Grb-2.(Crabtree and Clipstone, 1994;
Ravichandran et al., 1996; Weil and Veillette, 1996) As a consequence of antigen receptor-
induced tyrosine phosphorylation, two major signalling pathways are activated leading to
transcriptional events necessary for T-cell activation: (1) calcium/calcineurin (Beals et al.,
1997; Clipstone and Crabtree, 1992; Timmerman et al., 1996) and (2) ras/raf signal
transduction (Cantrell, 1996; Genot et al., 1996; Rayter et al., 1992; Woodrow et al.,
1993) (Figure 1). Briefly, calcineurin, a calcium/calmodulin dependent phosphatase, is
activated by a rise in intracellular calcium, allowing it to dephosphorylate the transcription
factor, NFAT (nuclear factor of activated T-cells). Upon its dephosphorylation, NFAT then
translocates to the nucleus, ready to complex with other transcriptional factors. Its
transcriptional partners are composed of Fos- and Jun-related protein heterodimers and in
contrast to NFAT, their expression is induced via the ras/raf pathway. Indeed, it has
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become evident that activation of both the calcium/calcineurin and ras/raf pathways results
in the formation of an NFAT/Fos/Jun complex that is competent to activate transcription of
an array of genes such interleukins-2 and 4.
Transforming Growth Factor - (TGF-) receptors
TGF-f receptor structure and function
In 1981, Roberts and Sporn isolated a class of growth factors identified as acid-
stable polypeptides potentiated by epidermal growth factor to induce transformation upon
fibroblasts on soft agar. These initial observations led to their christening as transforming
growth factors- (TGF-P1, -P2, -P3) Subsequently however, this initial designation
proved to belie its more prevalent effect on epithelial cells: potent growth inhibition.(Holley
et al., 1980; Ikeda et al., 1987; Roberts et al., 1985; Wrann et al., 1987) Experimental data
collected over the subsequent decade has revealed the complexity of the TGFs-; they
represent one of the most multifunctional peptide growth factors yet described, playing
roles in growth inhibition, wound healing, immune response, angiogenesis, embryonic
development and apoptosis. Moreover, they are the prototypical (founding) members of
what has become to be known as the TGF-P superfamily of growth factors including the
inhibins, activins, bone morphogenetic proteins, and MUllerian inhibitory substance.
These growth factors bind to two classes of surface receptors termed types I and II.
Each ligand binds and activates a particular pair of type I and type II receptors. The types I
and II receptors share a common structural design. Both classes of receptors possess a
short cysteine-rich extracellular domain followed by a single transmembrane domain and a
serine-threonine kinase-containing cytoplasmic domain. Unique to the type I receptors is a
glycine/serine rich region in the juxtamembrane region, termed the GS domain. To date, six
type I receptors, termed Alki through 6, have been identified.Although all can bind TGFs-
f when co-expressed with TPRII, only Alk-5 can signal. (ten Dijke et al., 1994)
The TGF-s also exert their effect through the binding of a type III receptor
(betaglycan) and its closely related sibling, endoglin. Both are transmembrane
proteoglycans with relatively short cytoplasmic domains. In contrast to the types I and II
receptors, their cytoplasmic domain lack any similarity to known signalling domains.
Hence it has been assumed that these receptors do not play a role in signalling; instead
evidence suggests that they bind ligand and subsequently present it to the types I and II
receptors, thereby increasing binding affinity of the receptor complex to TGFs-p.(Sankar et
al., 1995) Nevertheless, it is clear that they play an essential role in human development, in
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particular with respect to angiogenesis. Individuals afflicted with hereditary hemorrhagic
telangectasia (HHT) type I possess mutations in the gene encoding endoglin. These
individuals suffer from multisystemic vascular dysplasia resulting in gastro-intestinal
hemorrhaging and arterio-venous malformations, implicating endoglin involvement in
vascular development.(McAllister et al., 1995; McAllister et al., 1994)
Whether there are type III receptors for other TGF-3 ligands has yet to be
determined. However, there is evidence consistent with the existence of a type III-like
receptor expressed in vascular endothelial cells for activin-A .(McCarthy and Bicknell,
1994)
Employing orthogonal approaches, a number of studies have elucidated to a large
extent the sequence of events required for activation of the TGF-P receptor complex.
Specifically, the types I and II receptors appear to have evolved into two interdependent
signalling molecules. Each receptor is required for ligand-induced signalling. In particular,
type II is required for ligand binding whereas type I is necessary for initiation of
intracellular signalling. In binding and cross-linking studies, it has been established that
T RI (Alk-5) requires the presence of the type II receptor to bind the TGF-P
ligands.(Wrana et al., 1992) In the case of TGF-1 and TGF-3, TfRII first binds ligand
which then forms a ternary complex by recruiting TIRI into the TfRII/ligand complex. On
the other hand, TGF-2 appears to require co-expression of both types I and II to bind at
high affinities.(Rodriguez et al., 1995)
Studies measuring receptor kinase activity point to how recruitment of TPRI leads
to signal initiation.(Wrana et al., 1994) In particular, TPRII maintains high constitutive
kinase activity independent of the presence of ligand. In contrast, the T$RI kinase becomes
activated only after recruitment to the TPRII/ligand complex. This would suggest that
TfRII may be mediating transphosphorylation of TPRI upon formation of the ternary
complex. Indeed, when co-expressed with a kinase-defective T$RII, TIRI fails to become
phosphorylated. Yet, kinase-deficient and wild-type T3RI phosphorylation patterns are
indistinguishable when co-expressed with wild-type TIRII. Therefore, type II kinase
activity is necessary for TPRI phosphorylation most likely by direct transphosphorylation
of T$RI by RII. Signalling studies further demonsrate that TPRI phosphorylation and
therefore its activation constitute events downstream of initial TfRII/ligand
binding.(Franzen et al., 1993) Specifically, a clone (RIB) of a TGF-4 responsive mink
lung cell line expresses the type II, but not type I receptors; it fails to respond to TGF-$
stimulation as measured by growth inhibition or induction of early response genes such as
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plasminogen activator inhibitor-1 (PAI-1). However, transfection of TPRI cDNA into
RiBs is sufficient to restore signalling. Furthermore, transfection of a constitutively active
T3RI (threonine 204 to aspartate) is sufficient to exert TGF signalling in the absence of
TfRII or ligand further exemplifying the effector role of T3RI in the TGF-P receptor
complex.
The types I, II and III receptor all form ligand-independent homo-oligomers, most
likely dimers and upon TGF-P binding, form a types 1:11 heterotetramer. (Figure 1) (Gilboa
et al., 1998; Henis et al., 1994; Moustakas et al., 1993; Yamashita et al., 1994) Two
studies demonstrate the functional consequences of this particular receptor stoichiometry.
First, Luo and co-workers constructed chimeric receptors consisting of the extracellular
domain of the erythropoietin (Epo) receptor fused to the intracellular domain of either the
types I or II receptor. They show that Epo-induced hetero-dimerization of a type I chimera
with that of a type II can signal growth arrest.(Luo and Lodish, 1996) Moreover, a type I
chimera encoding for a constitutively active kinase still requires Epo-induced
homodimerization to signal. These results are consistent with the notion that the
requirements for TGF- signal transduction include both type I homodimerization as well
as its heterodimerization with type II. In another approach, Weis-Garcia et al. observe that
a kinase-defectve type I receptor mutant complements an activation-defective mutant when
co-expressed in cells. These results further confirm that type I homodimerization is indeed
essential for signalling (Weis-Garcia and Massague, 1996).
TGF-P signal transduction
Largely due to classical genetic analysis in Drosophila and Caernorhabtidis
elegans, key components of the signalling pathways emanating from the TGF- receptors
have been identified. Most notably, members of the SMAD family of proteins were initially
discovered from Drosophila by a genetic screen in which genes that enhanced the
phenotype of a mutation in a BMP2/4 homolog, Decapentaplegic (Dpp), were
isolated.(Raftery et al., 1995; Sekelsky et al., 1995) This screen yielded two highly
homologous genes: Mothers against dpp (MAD) and Medea. Both encode proteins that act
genetically downstream of dpp. Other members of this apparently growing family were
later isolated in C. elegans in a similar screen for mutants that exhibited phenotypes similar
to that of a type II receptor mutant.(Savage et al., 1996)
Within the past three years, these initial findings have led to rapid progress in the
cloning and characterization of eight mammalian SMAD genes.In particular, three sub-
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classes of SMADs have emerged: (1) pathway-restricted Smads (Smads 1,2,3,5 and 8), (2)
a partner protein that associates with receptor-activated SMADs (Smad 4) and (3) inhibitory
SMADs acting as negative regulators of TGF-P signalling (Smads 6,7). Mechanistically,
an activated type I receptor phosphorylates a specific SMAD. These receptor-associated
SMADs are pathway restricted as each one interacts with only a particular subset of type I
receptors. For example, only the TGF- and activin type I receptors can phosphorylate
Smads 2 and 3 whereas only the BMP receptors can phosphorylate Smads 1 and
presumably 5 and 8.(Baker and Harland, 1996; Chen et al., 1996; Eppert et al., 1996;
Holley et al., 1980; Kretzschmar et al., 1997; Liu et al., 1996; Liu et al., 1997; Nakao et
al., 1997; Suzuki et al., 1997; Watanabe et al., 1997; Zhang et al., 1996) Following their
phosphorylation, these SMADs then associate with Smad4 and translocate to the
nucleus.(Lagna et al., 1996; Zhang et al., 1996) By presumably associating with other
nuclear factors, the resulting complex then activates transcription of ligand-responsive
genes.
Although Smads 2 and 3 are highly homologous and can both associate with the
TGF- type I receptor, differences do emerge within the context of the developing
organism. Homozygous null Smad 2 mutant mice die early during
embryogenesis.(Nomura and Li, 1998; Waldrip et al., 1998) Smad3 mutant mice on the
other hand are viable and fertile until four months of age when they begin to develop
metastatic colorectal cancer.(Zhu et al., 1998)
Negative regulators, Smads 6 and 7, possess an amino terminal domain highly
divergent from other signalling Smads. They inhibit signalling by competing with pathway-
restricted SMADs in binding activated type I receptors.(Hayashi et al., 1997; Imamura et
al., 1997; Nakao et al., 1997) It has been proposed that by stably binding to these
receptors, they then prevent transphosphorylation of the downstream pathway-restricted
SMADs. Smads 6 and 7 can bind a number of type I receptors consistent with their
inhibition of multiple TGF-3 superfamily signalling pathways. Intriguingly, Smad 6 and 7
mediated inhibiton of TGF- signalling may be autoregulatory as TGF-P stimulation
induces their expression. An additional mechanism of inhibition has been proposed for
Smad6 as it is capable of binding Smadl and therefore may act as a non-functional Smad 4
decoy.
Several key aspects of Smad signalling require further study. For instance, the
SMAD proteins can homo as well as hetero-oligomerize. However, the precise
stoichiometry of these complexes remains to be fully determined.In vitro, Smad4 has been
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shown to form homotrimers.(Shi et al., 1997) Kawabata and co-workers find that in live
cells however, pathway-restricted Smads are monomers and undergo both homo- and
hetero-oligomerization upon activation.(Kawabata et al., 1998)
In addition, based on crystallographic data, Shi and co-workers demonstrate that
Smad3 binds a specific 4 base pair DNA sequence.(Shi et al., 1998) Because such low
DNA binding selectivity would be insufficient for specifically activating transcription of
TGF- -responsive genes, it is believed that additional transcription factors act in
combination with the SMAD complex to elicit gene expression. A model calling for such a
combinatorial approach would allow for the mediation of a wide range of ligand-induced
responses despite relatively low DNA sequence binding specificity for the SMAD family of
proteins. To date, two such candidate factors appear to fulfill this role. First, the winged
helix transcription factor FAST-I has been shown to mediate activin-induced gene
expression.(Chen et al., 1996; Chen et al., 1997; Chen et al., 1998) Specifically, FAST-I
is a nuclear protein and upon activin stimulation, associates with incoming Smads 2 and 4
to form a complex termed activin-response factor (ARF). The newly formed ARF then
activates transcription by binding to DNA sequence elements found within the promoter of
the Mix.2 gene, an activin early-response gene. Within the promoter, FAST- 1 binds a six
base pair sequence thereby augmenting the DNA binding specificity of the ARF complex.
A number of other activin responsive promoters appear to lack FAST-I binding sites in
close proximity to those of Smad2. This would suggest that other as of yet unidentified
factors may also complex with Smads2 and 4 to induce remaining aspects of the activin
induced response. Secondly, with respect to the TGF- pathway, Hua and co-workers
show that an E-box binding transcription factor called TFE3 cooperates synergistically with
Smads 3 and 4 to activate transcription of the TGF- responsive plasminogen activator
inhibitor-I (PAI-1) promoter.(Hua et al., 1998; Westerhausen et al., 1991) By studying the
transcriptional activity of PAI-I promoter mutants, they find that TFE3 and Smads3 and 4
bind to adjacent sites within a 36 bp element to induce TGF- dependent trancription.
Moreover, TFE-3 binds a specific six base pair DNA sequence within this element. This
further demonstrates the involvement of transcription factors that confer greater DNA
binding selectivity to SMAD containing complexes, a property presumably necessary for
mediating pathway specific responses.
Other molecules have been implicated to mediate TGF-P signalling. The
immunophilin, FKBP12, is one of the best characterized examples. Better known as a
target for various clinically relevant immunosuppressants, it also binds to a leucine-proline
sequence within the type I receptor GS domain preventing transphosphorylation by the type
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II receptor. Upon ligand-induced TPRI/T3RII association, it is then thought that FKBP12
dissociates from TfRI.(Chen et al., 1997; Wang et al., 1994; Wang et al., 1996) Mutant
type I receptors that are unable to bind FKBP12 exhibit high basal signalling activity
consistent with FKBP12's role as a negative regulator of TGF-$ signalling.(Chen et al.,
1997) Therefore, its function appears to lie in protecting the cell from spontaneous
signalling in the absence of ligand.
Three other proteins have been shown to be capable of directly associating with the
TGF- receptors. p21RAS farnesyl protein-transferase a has been shown to bind the type
I receptor and both TRIP-1, a WD-domain containing protein, and apolipoprotein J have
been shown to bind to the type II receptor.(Chen et al., 1995; Kawabata et al., 1995;
Reddy et al., 1996; Ventura et al., 1996; Wang et al., 1996) However, the functional
significance of these interactions have yet to be elucidated.
TGF-P responses
The multipotent TGF- signals can be classified into immediate and secondary
effects. With regard to immediate effects, the TGFs-3 inhibit growth by arresting the cell
cycle at the GI to S transition. Specifically, inhibitory signals are transmitted through two
independent pathways: (1) the upregulation of CDK inhibitors, p15 together with either
p21 or p27, and (2) the repression of a CDK tyrosine phosphatase, CDC25a.(Figure 2)
(Datto et al., 1995; Hannon and Beach, 1994; lavarone and Massague, 1997) Both
pathways apparently converge to the negative regulation of cyclin-dependent kinases
(CDKs) 4 and CDK6. Activation of CDKs-4 and 6 are necessary for phosphorylation of
the retinoblastoma (Rb) protein and subsequent entry to S phase. Therefore, it appears to
be at the level of CDK activity, a key junction of the cell cycle machinery, that TGF-P
exerts it primary negative growth control.
With certain cell types, TGFs-3 also impinge second order effects including
extracellular matrix production, immunosuppresion, and induction of angiogenesis.(Huber
et al., 1992; Khanna et al., 1998; Roberts et al., 1986; Tashjian et al., 1985) Under
particular circumstances, opposing secondary effects such as the induction of platelet
derived growth factor secretion can overcome this block in cell cycle progression hence
explaining earlier seemingly contradictory observations documenting the TGF-I induction
of transformation upon fibroblasts.
TGF-Ps and human pathogenesis
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The most striking validation of the current model for TGF- signalling can be
illustrated by mutations of genes implicated in the signalling pathway and their resulting
disease manifestations. It is believed that cells harboring mutations that render them
unresponsive to TGF- are endowed with a significant growth advantage over their
responsive counterparts. Indeed, loss of TGF- responsiveness is a common hallmark of
various cancers.
On the receptor level, mutations in the type II receptor have been isolated from
tumors of the colon, head and neck, T-cell lymphomas and gastric cancers, substantiating
their role as tumor suppressors in a variety of cancers.(Garrigue-Antar et al., 1995; Knaus
et al., 1996; Lu et al., 1998; Park et al., 1994) Furthermore, type II receptor mutations are
found in 90% of all colon cancers exhibiting microsatellite instability.(Markowitz et al.,
1995; Wang et al., 1995) The high mutation frequency observed does not appear to be due
to an inherent susceptibility of the type II receptor gene to mutations. Rather, only
gastric/colon cancers exhibit high mutation frequencies whereas other cancers arising from
microsatellite instability do not. This would suggest that type II receptor mutations are
somehow selected for in gastric and colon cancers. Mutations appear to occur late in
tumorigenesis suggesting that the TGF-P pathway plays a role in malignant progression
rather than tumor initiation.(Grady et al., 1998) Whether the type I receptor is likewise a
primary target for inactivating tumors in cancers is not as well established. However,
Schiemann and co-workers have recently isolated a type I receptor mutation from a TGF- -
resistant T-cell lymphoma [manuscript in preparation]. And indeed, these mutations were
demonstrated to result in the loss of type I receptor expression.
The relevance to cancer of the SMAD family of proteins became apparent shortly
after their isolation in Drosophila and C. elegans. As one of the first vertebrate SMADs to
be identified, SMAD4 was discovered as a gene in which both alleles were deleted in 90%
of human pancreatic carcinomas.(Hahn et al., 1996) Subsequent studies in mice reinforce
the essential role played by SMAD4 in the TGF-P pathway. Specifically, Takaku and co-
workers show that tumors homozygously deficient for both SMAD4 and another tumor
suppressor gene, APC, caused larger and more rapidly progressing carcinomas than in
mice homozygously deficient for only APC(Hahn et al., 1996) These results therefore are
consistent with SMAD4 playing a key role in the rate of tumor progression. Among
pathway specific SMADs, SMAD2 has also been shown to be a target of inactivating
mutations in colon cancers.(Eppert et al., 1996; Riggins et al., 1997; Uchida et al., 1996)
23
Intriguingly, despite the fact that SMAD3 knock-out mice develop metastatic colorectal
cancer, no mutations have been identified in human cancers thus far.
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Chapter 2
Zinc is essential for binding of p5 61ck to CD4 and CD8c
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Abstract
Binding of the protein tyrosine kinase p5 6 lck to T-cell co-receptors CD4 and CD8X is
necessary for T-lymphocyte development and activation. Association of p561ck with CD4
requires two conserved cysteine residues in the cytosolic domain of CD4 and two in the
amino-terminus of p561ck, consistent with the notion that these four residues coordinate a
single metal atom (Huse et al., 1998; Rudd et al., 1988; Shaw et al., 1989; Turner et al.,
1990; Veillette et al., 1988). Here we demonstrate that Zn 2 + is essential for complex
formation. In an in vitro binding reaction, Zn 2 + mediates p561ck association with a GST
fusion protein containing the cytosolic domains of CD4 or CD8X; no other metals tested
support binding. Treatment of preformed GST-CD4/p561ck dimers with the Zn 2 +
chelators 1,10 0-phenanthroline or 8-hydroxyquinoline-5-sulfonic acid results in
dissociation of GST-CD4 from p561ck, consistent with the finding of (Huse et al., 1998)
that Zn2 + is contained within similar complexes. Furthermore, we show that within live
cells, CD4/p56lck and CD8/p561ck interactions occur in a zinc-dependent fashion.
Specifically, pretreatment of the human T-cell Jurkat cell line with membrane permeable
zinc chelators disrupts CD4/p561ck complexes, and treatment of COS cells co-expressing
CD8x and p561ck with such chelators likewise leads to dissociation of CD8o/p561ck
complexes. CD4/p56lck and CD8o/p56lck represent the first examples of intracellular
proteins that require zinc as a bridge for heterodimerization.
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Introduction
T-lymphocyte activation requires the coordination of a large complex of proteins
collectively termed the T-cell receptor (TCR). Within the TCR, activation of p561ck, a
lymphocyte-specific member of the Src family of non-receptor protein tyrosine kinases, is
necessary for initiation of signal transduction. By binding to the cytosolic domains of CD4
and CD8c, p561ck is placed in close proximity to its downstream substrates, CD3, TCR (
chain and Zap70. They, in turn, activate subsequent signaling events (Weil and Veillette,
1996; Weiss and Littman, 1994).
Association of p56lck with CD4 requires two conserved cysteine residues in the
cytosolic domain of CD4 and two in the amino-terminus of p561ck (Rudd et al., 1988;
Shaw et al., 1989; Turner et al., 1990; Veillette et al., 1988). Mutation of any of these
four cysteines results in failure to form a CD4/p561ck complex (Barber et al., 1989; Shaw
et al., 1989; Veillette and Fournel, 1990). These cysteines and their spacing within each
domain are highly conserved, yet mutation of adjacent residues has no effect on
CD4/p561ck association (Shaw et al., 1989; Shaw et al., 1990; Turner et al., 1990). Given
the strongly reducing environment in the cytosol of eukaryotic cells, formation of
intermolecular disulfide bonds between CD4 and p56lck is unlikely (Hwang et al., 1992).
Treatment of cell lysates with iodoacetamide, a reagent that alkylates free cysteines,
prevents binding of p561ck to the cytosolic domain of CD4. This finding suggests that the
cysteines involved in association remain reduced in the CD4/p56lck complex and raises the
possibility of a metal ion stabilizing the complex (Shaw et al., 1990). Recently, Huse et al.
(1998) co-expressed in Escherichia coli a fusion protein consisting of maltose binding
protein fused to the CD4 cytoplasmic domain and a portion of the N-terminus of p56lck;
the resulting 1:1 molar complex contained one atom of zinc and formation of the complex
required cysteine residues both in the CD4 cytoplasmic domain and the N-terminus of
p5 6 1ck.
Here, we show that Zn++ is essential for CD4/p56lck complex formation, both in
cell-free binding assays and in live cells. In addition, we present evidence showing that
formation of a CD8W/p56lck complex is similarly dependent on Zn2 +.
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Experimental Procedures
Cells
Jurkat cells (American type culture collection; Clone E6- 1, human acute T-cell leukemia)
were grown to a density of ~106 cells/ml in RPMI-1640 medium containing 10% fetal calf
serum, 5 mg/ml glucose, 100 units/ml penicillin and 100 gg/ml streptomycin. Fifty ml of
culture was processed for each data point.
Construction of GST-CD4 and GST-CD8afusion proteins and in vitro binding reactions.
By PCR a cDNA encoding the 37 residue cytoplasmic domain of murine CD4 was
generated and inserted into the EcoRI and NotI sites of the Pharmacia pGEX-4T1 vector.
The resulting ligation produced an in-frame fusion protein with glutathione S-transferase
(GST). Forward and reverse primers mutating cysteines 418 (C418A) and 420 (C420A)
to alanine were generated. Using these primers, double and single cysteine to alanine
mutations in the cytoplasmic domain of CD4 were generated by overlap PCR. Similarly, a
cDNA encoding the 27 amino acid cytoplasmic domain of orangutan CD8c was inserted
in-frame with that of GST at the same site in the above Pharmacia vector. GST-CD4,
GST-CD8x, and GST alone were expressed in E. Coli DH1OB. After one hour induction
with 1 mM isopropyl B-D thiogalactopyranoside (IPTG) at 37'C, proteins were purified as
previously described (Smith and Johnson, 1988) and immobilized to glutathione-
Sepharose 4B (Pharmacia) at 4'C for 1 hour. After washing 15 jg of immobilized protein
three times with TBS-GT (137 mM NaCl, 20 mM Tris-HCl [pH 8.0], 1% Triton X-100,
10% glycerol) (Turner et al., 1990), the slurry was resuspended in 500 jl of TBS-GT
containing 1 jg of purified bovine p56lck (10 gl solution containing -100 gg/ml or 500
units/ml; Upstate Biotechnology, catalog #14-106), and the indicated concentrations of
ZnCl2 or other metals. These binding reactions contain GST-CD4 or GST-CD8X at an
approximately 20 to 1 molar excess over p561ck. Following incubation at 4'C for 8 hours,
samples were washed with TBS-GT three times and TBS once. Samples were analyzed by
8% SDS-PAGE (Laemmli, 1970) and transferred by semi-dry electrophoresis to 0.22 gm
porosity nitrocellulose. The membrane was blocked with Buffer A [1 mM KH2PO4, 10
mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, 0.5% Tween-20, and 3% non-fat
powdered milk, pH 7.0] followed by incubation with 0.5 pig/ml of an anti-human p5 6 1ck
monoclonal antibody (Santa Cruz Biotechnology, catalog #SC-433) for 3 hours at room
temperature. After washing 5 times with Buffer A, a 1:5000 dilution of goat anti-mouse
secondary horse radish peroxidase antibody (Amersham) was added for 2 hours at room
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temperature. The membrane was washed three times with Buffer A and two times with
PBS; bound antibodies were detected by addition of an ECL substrate as specified by the
manufacturer (Pierce). Autoradiographic films were analyzed by using a Bio-Rad GS-700
flatbed scanner together with Molecular Analyst v2.1 software (Bio-Rad).
Immunoprecipitation (IP) and immunoblotting
About 5 x 10 7 Jurkat cells or 108 COS-7 cells were lysed in 1 ml of TBS-GT containing 1
mM phenylmethylsulfonyl fluoride (PMSF). Antibodies were preincubated with 50 pl/IP
of protein-A sepharose for 15 minutes at 4'C. After a 5 minute centrifugation, cleared
lysates were incubated with the antibody/protein-A sepharose mixture for - 2 hours at 4'C.
Antibodies used were: anti-human p56lck polyclonal antibody (Upstate Biotechnology,
catalog #06-583, 2 [1 per IP), anti-human CD4 polyclonal antibody (Immunodiagnostics,
catalog #7301, 5 p1 per IP), and anti-mouse CD8c polyclonal antibody (5 g1 per IP)
(Sarmiento et al., 1980). After incubation at 4'C, immunoprecipitates were washed three
times with TBS-GT followed by one wash with TBS. Immunoprecipitates were separated
by 8% SDS-PAGE, transferred to nitrocellulose, and immunoblotted with an anti-p561ck
antibody as described above.
COS cell transfections
Using the DEAE/dextran method, COS-7 cells (American Type Culture Collection) were
transiently transfected (Seed and Aruffo, 1987) with 10 jig of DNA: either murine p561ck
in the vector pXM-139 (unpublished data, Veillette et al.), 10 jig of p561ck (C20/23S) in
pcDNA3.1 (Invitrogen), or 10 gg of CD8o (Lyt2a) in pCDNA3.1. p561ck(C20/23S)
contains mutations in which cysteines 20 and 23 are mutated to serine (Gervais and
Veillette, 1995). Forty-eight to 72 hours after transfection, the cells were washed once
with PBS and lysed in TBS-GT containing 1 mM PMSF. After a 5 minute centrifugation
at 4'C, cleared lysates were incubated with 15 gg of immobilized GST-CD4 overnight at
4'C. Samples were then washed and assayed for bound p5 6 1ck as described above. In
other studies, cleared lysates were immunoprecipitated with anti-p56lck or anti-CD8u.
antibodies and processed for p56lck immunoblotting as described above.
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Results
Figure IA shows the results of an in vitro binding reaction, demonstrating that
indeed Zn++ mediates the association of the cytoplasmic domain of CD4 and p56lck in a
concentration-dependent manner. Recombinant glutathione S-transferase (GST) fused to
the cytoplasmic domain of murine CD4 was produced and purified from Escherichia coli
followed by immobilization on glutathione sepharose. As detected by immunoblotting with
an anti-p56lck antibody, association of purified bovine p5 61ck with GST-CD4 depends
upon the presence of 100 kM ZnC12. At this ZnCl2 concentration almost 100% of the
introduced p561ck becomes bound to GST-CD4. The detected p561ck band is not a
contaminant of the GST-CD4 preparation as no binding is seen in the absence of p561ck,
and GST alone does not bind p561ck. Furthermore, other metals tested at 100 RM,
including Ca 2 +, Ni2 +, Cu+, Cu 2 +, and Fe2 +, do not support complex formation (Figure
IB), suggesting that association of CD4 with p561ck specifically requires zinc.
Consistent with previous findings, our in vitro binding reaction recapitulates the
critical role in association played by the four conserved cysteines. In particular, Figure 2A
shows that immobilized GST-CD4 binds murine p56lck expressed in lysates of transfected
COS cells, but fails to interact with a mutant p56lck in which the two essential cysteines,
implicated in binding to CD4 and CD8cc, were mutated to serine. Additionally, mutants of
the CD4 cytoplasmic domain in which either one or both conserved cysteines were
changed to alanine lose significant binding to p561ck (Figure 2B). Nevertheless, all
mutants exhibited some residual binding. Furthermore, the presence of 1 mM $-
mercaptoethanol in the binding reaction had no effect on formation of a CD4/ p56lck
complex (data not shown), consistent with the notion that the cysteines necessary for
association are reduced within the formed complex.
Moreover, the presence of Zn 2+ chelators both prevents complex formation as well
as disrupts preformed ones. As shown in Figure 2A, GST-CD4/p561ck complex
formation is blocked by addition of the zinc chelator 1,10 0-phenanthroline to COS cell
lysates expressing wild type p561ck. Furthermore, pre-formed CD4/p56lck complexes are
disassociated by similar treatment. In the study in Figure 3A, GST-CD4/p561ck complexes
were formed and then treated with the zinc chelators 8-hydroxyquinoline-5-sulfonic acid
or 1,10 0-phenanthroline or a non-chelating analog, 1,7 phenanthroline. Only 1,10 0-
phenanthroline and 8-hydroxyquinoline-5-sulfonic acid disassociated pre-formed
CD4/p56lck dimers. These findings suggest that removal of Zn++ disrupts CD4/p561ck
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complexes; disruption cannot be attributed to non-chelating properties of 1,10 0-
phenanthroline such as its hydrophobicity, a characteristic shared with 1,7 phenanthroline
(Auld, 1988). Thus Zn++ is required for CD4/p561ck interaction and its removal from the
complex results in their dissociation.
Figure 3B shows that, in signaling lymphoid cells, CD4/p561ck complexes are
disrupted by addition of the membrane permeable zinc chelators TPEN and 1,10 0-
phenanthroline; importantly, 1,7 phenanthroline, a non-chelating analog, or EDTA, a
membrane-impermeable chelator, has no effect on CD4/p561ck complexes. Specifically, as
judged by co-immunoprecipitation with CD4, treatment of living Jurkat cells with TPEN
or 1,10 O-phenanthroline eliminated binding of p56lck to CD4. However, 1,7
phenanthroline or EDTA exhibited no such effect. The total amount of p561ck in the cell
was unaffected by any of the treatments, as shown by immunoprecipitation with and
immunoblotting with anti-p56lck antibodies. We have obtained the same results with
murine p56lck and CD4 co-transfected in COS cells (Figure 3C). Thus, both in vitro and
in living cells, zinc chelators disrupt association of CD4 with p561ck, presumably by
chelating an essential Zn2+ ion present in the complex.
The cytosolic domains of the T-cell CD8L and CD4 co-receptors possess a
homologous pair of cysteine residues, suggesting that they dimerize with p561ck in a
similar manner. Indeed, in COS cells transiently transfected with CD8a and p5 6lck,
p561ck binds to CD8o and this interaction is disrupted by 1,10 0-phenanthroline, but not
1,7 phenanthroline (Figure 4A). Importantly, CD8x does not associate with the mutant
p561ck(C20,23S) lacking the two cysteines essential for interaction with CD4 (Figure 4A).
This control also establishes that CD8x/p561ck interactions cannot be attributed to non-
specific aggregations that are often associated with protein over-expression.
As with that of CD4, the cytosolic domain of CD8x also associates with p5 6lck in
vitro but requires a ten-fold higher ZnCl2 concentration to support binding - 1 mM versus
100 gM (Figure 4B). At the same concentration, other metals such as Cu2 +, Ca2 +, and
Co2 + do not support binding (data not shown).
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Discussion
Our work builds on previous studies implicating a role for Zn2 + or another metal
ion in mediating an interaction between the short cytoplasmic domains of CD4 and CD8x
with p561ck. First, the cytoplasmic domains of CD4 and CD8x and the N-terminal region
of p561ck each contain a pair of cysteines that are essential for CD4/p561ck and
CD8/p561ck interactions (Rudd et al., 1988; Shaw et al., 1989; Turner et al., 1990;
Veillette et al., 1988). Second, alkylating agents that inactivate free cysteine sulfhydryl
groups destroy CD4/p561ck interactions (Shaw et al., 1990). Third, Huse et. al. (Huse et
al., 1998) identified a 1:1 molar complex of the CD4 cytoplasmic domain and a portion of
the N-terminus of p561ck when these were co-expressed in Escherichia coli . Complex
formation required cysteine residues both in the CD4 cytoplasmic domain and the N-
terminus of p561ck, and each protein complex contained one atom of zinc. However, Huse
and colleagues were unable to assemble the CD4/p561ck complex in vitro and thus were
unable to determine whether zinc or another metal is required for complex formation (S.
Harrison, personal communication).
Here, we show that formation of a complex - presumably a dimer - of the
cytoplasmic domain of CD4 and the complete p561ck protein specifically requires the
presence of zinc. We first developed an in vitro binding assay which recapitulates the
critical role in association played by the two cysteines in CD4 and two at the N- terminus
of p561ck. Only Zn2 +, and none of the other metals tested - Ca2 +, Ni2 +, Cu+, Cu 2 +, and
Fe 2 + - supported CD4/p561ck association. Moreover, Zn2 + chelators both prevent
association as well as disrupt preexisting CD4/p561ck complexes. Likewise, in live
signaling cells, membrane permeable zinc chelators dissociate CD4/p561ck complexes,
presumably by removing zinc. In conjunction with (Huse et al., 1998), our data firmly
establish a role for Zn++ in mediating CD4/p561ck association through the coordination of
two cysteines in the CD4 cytoplasmic domain and two in the N-terminus of p5 6 1ck.
The N-terminus of p561ck contains a strikingly high density of acidic, negatively
charged residues whereas the cytoplasmic domains of both CD4 and CD8o contain a high
density of basic residues. This charge complementarity (Bramson et al., 1991; Vega et al.,
1990) may stabilize the interactions of p561ck with CD4 and CD8c and may explain the
weak but specific interactions we detected in vitro between p561ck and mutants of CD4 in
which one or both of the essential cysteines were changed to alanine. The elevated
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concentrations of both GST-CD4 and p5 6 1ck used in these binding assays could favor
formation of such complexes.
The relatively high zinc concentrations required for binding of p561ck to GST-CD4
(10-100 gM Zn++) or GST-CD8x (100 gM to 1 mM Zn++) are comparable to that
required for HIV Tat homodimerization - 100 gM Zn2 +; this is the only other intracellular
protein-protein interaction thus far characterized that requires zinc as a bridge for
dimerization (24, 25). In addition, we found (unpublished) that glutathione S-transferase
alone can bind zinc.Thus, the actual concentrations of free Zn2 + in our GST-CD4/p561ck
and CD8/p56lck binding assays may be lower than the added Zn2 + concentrations.
Nevertheless, these high concentrations may reflect differences in association that occur in
vitro versus in live cells. In live cells, factors such as myristylation of p561ck and its
consequent insertion into the plasma membrane may contribute to the stability of the
complex, as could association of p5 6 1ck with the TCR Q chain. More intriguingly, Vallee
and co-workers showed that, under oxidizing conditions similar to those in the
endoplasmic reticulum, zinc can be transferred from its binding site in metallothioneins to
those of lower affinity in other zinc proteins. Hence, inside the cell where the
concentrations of free zinc are in the picomolar range, metallothioneins may play a role in
transferring zinc to proteins during their biosynthesis (Jacob et al., 1998; Jiang et al.,
1998; Maret et al., 1997; Maret and Vallee, 1998).
Furthermore, we show that CD8x interacts with p56lck in an analogous zinc-
dependent manner to CD4. In vitro, association of GST-CD8x with p561ck specifically
requires zinc; other metals tested do not support binding. In living cells, CD8W/p561ck
complexes are disrupted by membrane-permeable zinc chelators. The higher zinc
concentration required for formation of the CD8x/p561ck than the CD4/p561ck complex
leads us to speculate that, under limiting zinc concentrations, p561ck binding to CD8X
would be of lower affinity than to CD4. This is supported by studies showing that a
greater proportion of total cellular p561ck associates with CD4 than with CD8X (50-90%
versus 10-25% for CD4 and CD8x, respectively) (Rudd et al., 1988; Veillette et al.,
1988). Furthermore, only the mutation of both conserved cysteines in CD8c entirely
abolishes p56lck association (Turner et al., 1990). These observations suggest that the
nature of zinc binding in the CD8c/p561ck complexes may not be identical to that in
CD4/p561ck.
Finally, our studies show that membrane-permeable Zn 2 + chelators rapidly and
completely disrupt CD4/p561ck complexes in lymphoid cells. Thus, TPEN and 1,10 0-
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phenanthroline may serve as useful tools to dissect TCR signaling in the absence of CD4-
mediated p56lck activation.
The CD4/p561ck and CD8c/p561ck dimers are, to our knowledge, the first
examples of intracellular protein heterodimers bridged by zinc. CD4/p561ck complexes
form in the endoplasmic reticulum within ten minutes of CD4 biosynthesis (Shaw et al.,
1989). As yet we do not know what role, if any, zinc might play in folding of CD4,
CD8x, and p561ck, nor do we know the stage of biosynthesis where zinc links the two
proteins together. Structural studies are needed to elucidate the details of the Zn2 +-
containing interface between p56lck and either CD4 or CD8x; the HIV Tat protein may
serve as an informative model with which to begin such structural studies. In the presence
of 100gM ZnCl2,Tat forms a homo-dimer in vitro bridged by 4 Zn2 + ions (Frankel et al.,
1988; Frankel et al., 1988). Biophysical measurements indicate that little change in
secondary structure occurs upon complex formation, suggesting that metal binding does
not significantly alter global protein folding. With respect to association of p561ck with
CD4 or CD8u, it is possible that zinc may likewise simply serve as a molecular "adhesive"
by which to bridge two proteins.
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Figure Legends
Figure 1: Interaction of GST-CD4 and p5 6 lck in vitro requires zinc.
A) GST-CD4/p561ck interaction requires the presence of ZnCl2. Reactions
contained 1 gg purified bovine p5 6lck, either 15 jtg of immobilized GST-CD4 or GST
alone, and the indicated concentration of ZnCl2. p5 6 1ck bound to the glutathione beads
was subjected to Western blotting with an anti-p56lck antibody. The right most lane
contains 1 xg of p561ck as a control for efficiency of binding; the first lane on the left
depicts a control reaction containing GST-CD4 and 100 gM ZnCl2, but no p561ck.
Samples were processed and assayed for bound p561ck as described in Experimental
Procedures.
B) The GST-CD4/p56lck complex forms only in the presence of zinc.
Fifteen gg of immobilized GST-CD4 or GST alone was incubated in 500 gl of TBS-GT
containing 1 jig p561ck and 100 jM of the indicated divalent metal for 8-12 hours at 4'C.
Samples were processed and assayed for bound p56lck as described in Experimental
Procedures.
Figure 2: Association of p561ck with GST-CD4 requires two conserved
cysteine residues in the cytosolic domain of CD4 and two in the amino-
terminus of p561ck
A) Interaction of p56lck expressed in COS-7 cells with GST-CD4.
COS-7 cells were transiently transfected with either murine p561ck in pXM-139 or p561ck
(C20/23S) in pcDNA3. 1. Forty-eight hours after transfection, the cells were washed once
with PBS and lysed; in the indicated sample, 5 mM 1,10 0-phenanthroline was added.
After centrifugation at 4'C the cleared lysates were incubated with 15 jig immobilized
GST-CD4 overnight at 4C. Samples were then washed and assayed for bound p561ck.
B) Interaction of p561ck with cysteine mutants of GST-CD4.
In 500 jl of TBS-GT containing 100 pM ZnCl2, 1 jg of p561ck was incubated with 15
jg of GST, GST-CD4, GST-CD4 (C418A,C420A), GST-CD4 (418A) or GST-CD4
(C420A) for 8 hours at 4C. Samples were processed and assayed for bound p561ck as
described in Experimental Procedures.
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Figure 3: Interaction of CD4 and p5 6 lck is disrupted by zinc chelators
A) Zinc chelators disrupt preformed GST-CD4-p56lck complexes.
As described in Figure IA, GST-CD4/p561ck complexes were formed at 100 RM ZnC12.
After washing three times with TBS-GT, bound complexes were resuspended in 500 Rl of
TBS-GT alone, with 5 mM 1,7 phenanthroline, with 5 mM 1,10 O-phenanthroline, or
with 5 mM 8-hydroxyquinoline-5-sulfonic acid. After a ten minute incubation at 4'C,
samples were washed three times with TBS-GT and once with TBS. Samples were
washed and assayed for bound p561ck as described in Experimental Procedures.
B) Membrane-permeable chelators disrupt p561ck-CD4 complexes in Jurkat
cells.
Jurkat cells were concentrated by centrifugation and resuspended in 10 ml of RPMI-1640
alone or with either 5 mM EDTA, 5 mM TPEN, 5 mM 1,7 phenanthroline or 5 mM 1,10
0-phenanthroline. Cells were incubated at 37'C for 10 minutes, recovered by
centrifugation, washed with PBS and recovered once more prior to lysis. Of the cleared
lysates 200 jil was immunoprecipitated with an anti-human p561ck polyclonal antibody
and the remaining 800 Rl was immunoprecipitated with an anti-human CD4 polyclonal
antibody. Immunoprecipitations and subsequent anti-p56lck immunoblotting were
performed as described in Experimental Procedures.
C) Treatment of COS cells co-expressing CD4 and p56lck with 1,10 0-
phenanthroline disrupts their association.
COS-7 cells were transiently co-transfected with murine CD4 in pcDNA3.1 and either
p56lck in pXM- 139 (unpublished data, Veillette et al.). Forty-eight hours after transfection
the cells were washed once with PBS and incubated in DME alone or with 5 mM 1,10 0-
phenanthroline for 10 minutes at 37'C. Cells were then washed once in PBS and lysed.
Half of the lysate was subjected to immunoprecipitation with an anti-mouse CD4
polyclonal antibody (T4-4 (Deen et al., 1988; Willey et al., 1992); NIH AIDS Research
and Reference Reagent Program; catalog#805) and half with an anti-human p561ck
polyclonal antibody. Immunoprecipitations and immunoblotting were performed as
described in Experimental Procedures.
Figure 4: CD8cx/p561ck interaction is zinc dependent
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A) Treatment of COS cells co-expressing CD8a and p56lck with 1,10 0-
phenanthroline disrupts their association.
COS-7 cells were transiently co-transfected with CD8x (Lyt2a) in pcDNA3.1 and either
murine p5 6 1ck in pXM-139 (unpublished data, Veillette et al.) or murine p561ck(C20/23S)
in pCDNA3. 1. Forty-eight hours after transfection the cells were washed once with PBS
and incubated in DME alone or with either 5 mM 1,7 phenanthroline or 5 mM 1,10 0-
phenanthroline for 10 minutes at 37'C. Cells were then washed once in PBS and lysed.
Half of the lysate was subjected to immunoprecipitation with an anti-mouse CD8X
polyclonal antibody (Sarmiento et al., 1980) and half with an anti-human p5 6 1ck
polyclonal antibody. Immunoprecipitations and immunoblotting were performed as
described in Experimental Procedures.
B) Association in vitro of GST-CD8a with p5 6Ick requires zinc
GST-CD8x and GST were produced and isolated as described in Experimental
procedures. Binding was performed in the same fashion as with GST-CD4 with the
exception that at 1 mM ZnCl2, we readjusted the pH of the buffer with 1M Tris-HCl, pH
8.0. Lane 6 is a control containing 1 jig p561ck. Samples were processed and assayed for
bound p561ck as described in Experimental Procedures.
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Chapter 3
Chemical dissection of TGF-P receptor complex formation
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Abstract
The TGF-s mediate a diversity of biological responses through the binding of a types I
(T3R 1) and II (TPRII) receptor. Specifically, these cytokines bring about the formation of
a signalling complex consisting of a T3RI and TIRII heterocomplex - most likely a
heterotetramer. (Gilboa et al., 1998; Henis et al., 1994; Moustakas et al., 1993; Yamashita
et al., 1994) It has been shown that pre-treatment of cells with DTT blocks functional
recruitment of TPRI to a TGF-P 1 bound TfRII resulting in a complex unable to signal.
(Cheifetz et al., 1990; Wells et al., in press) In this study, we further report that formation
of pre-formed complexes is also blocked by DTT as similar pre-treatment abrogates binding
of both TPRI and TPRII to TGF-P2, a ligand distinct from TGF- 1 in that it requires co-
expression of both receptors to bind.(Rodriguez et al., 1995) To identify the properties of
DTT required to elicit this phenomenon, we screened a number of chemically related
reducing agents for a similar inhibitory effect upon complex formation. Here, we find that
2,3 DMP (2,3 dimercaptopropanol) likewise blocks functional interactions between TfRI
and TPRII. Both it and DTT are di-thiol based compounds that are membrane-permeable.
However, other thiol-containing compounds lacking either one of these properties exert no
effect on complex formation. In addition, DTT does not affect TPRI homodimerization, an
upstream event required for TfRI.TPRII hetero-oligomerization. Hence, this would
suggest that mechanistically, DTT and similarly, 2,3 DMP, act upon intracellular factor(s),
and through chemical properties related to the presence of di-thiols, inhibit TfRI-TPRII
association. The cytoplasmic domain of TPRI plays a critical role in these interactions as
we find that a cytoplasmically truncated TfRI fails to associate with ligand-bound TfRII.
In contrast, the TfRII cytoplasmic domain is dispensable for complex formation (Wieser et
al., 1993), nor is it required to manifest the DTT effect. Therefore, we propose that DTT
directly acts upon structural elements contained within TfRI's intracellular domain that are
required for functional TPRIeTPRII interactions.
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Introduction
The TGF-Ps (TGF-P 1, -P2, -P3) constitute one of the most multifunctional peptide
growth factors yet described, playing roles in growth inhibition, wound healing, immune
response, angiogenesis, embryonic development and apoptosis. (Roberts, 1990) They are
also the founding members of what has become to be known as the TGF-P superfamily of
growth factors including the inhibins, activins, bone morphogenetic proteins, and
MUllerian inhibitory substance.
The TGF-Ps bind to two surface receptors termed types I (TPRI) and II (T$RII).
The types I and II receptors share a common structural design. Both classes of receptors
possess a short cysteine rich extracellular domain followed by a single transmembrane
domain and a serine-threonine kinase-containing cytoplasmic domain. Unique to the type I
receptors is a glycine/serine rich region in the intracellular juxtamembrane region, termed
the GS domain.
Each receptor is required for ligand-induced signalling as TPRII is required for
ligand binding whereas TPRI is necessary for initiation of intracellular signalling. Binding
of the ligand TGF-P 1 to the type II receptor causes it to associate with and phosphorylate
the type I receptor. This interaction is essential for TGF-P-activated signal
transduction.(Wrana et al., 1994) Both TPRI and TPRII form ligand-independent homo-
oligomers, most likely dimers and upon TGF-P binding, pairs of types I and II receptor are
presumably brought together to form a heterotetramer. (Gilboa et al., 1998; Henis et al.,
1994; Moustakas et al., 1993; Yamashita et al., 1994) Homodimerization of the type I is
receptor required for TGF-P signalling. Two studies demonstrate the functional
consequences of its dimerization. First, Luo and co-workers constructed chimeric receptors
consisting of the extracellular domain of the erythropoietin (Epo) receptor fused to the
intracellular domain of either the types I or II receptor.(Luo and Lodish, 1996) They show
that Epo-induced hetero-dimerization of type I and II chimeras can signal growth arrest.
Moreover, a type I chimera encoding for a constitutively active kinase still requires Epo-
induced homodimerization to signal. These results are consistent with the notion that the
requirements for TGF-P signal transduction include both type I homodimerization as well
as its heterodimerization with type II. In another approach, Weis-Garcia et al. observe that
a kinase-defective type I receptor mutant complements an activation defective mutant when
co-expressed in cells. These results further confirm that type I homodimerization is indeed
essential for signalling.(Weis-Garcia and Massague, 1996)
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Whether ligand plays a role in recruiting both receptors into a functional complex
and/or stabilizing pre-existing complexes remains unresolved. Despite evidence pointing
towards ligand-induced TPRI*TPRII association, a number of overexpression studies also
detect the existence of ligand independent complexes on the cell surface.(Chen and
Weinberg, 1995; Ventura et al., 1994; Wells et al., in press) Moreover, TGF-2 binding
requires the presence of both types I and II receptors providing further evidence for pre-
formed complexes on the cell surface.(Rodriguez et al., 1995)
It is known that DTT abrogates binding and cross-linking of TGF-- 1 to TfRI.
(Cheifetz et al., 1990) Wells and co-workers suggest that DTT induces conformational
changes in the complex rendering it incapable of signalling and more readily dissociated in
the presence of detergent. (Wells et al., in press)
In this study, we wish to first further elucidate the mechanism by which DTT elicits
this phenomenon, and secondly, to use this compound as a means to identify structural
elements contained within TfRI and TfRII that are necessary for formation of a complex
competent to signal. Our findings provide additional evidence that DTT significantly
compromises functional interactions between both receptors as measured by both ligand
binding and consequent downstream signal transduction. Secondly, we find that 2,3
dimercaptopropanol (2,3 DMP), a thiol-based compound chemically related to DTT, also
exerts an inhibitory effect upon ligand binding to T3RI and downstream phosphorylation
events. Both compounds are membrane permeable and contain dithiols. Results from
analyzing other classes of thiol-based reducing agents suggest that both properties are
involved in manifesting the observed effects. We also report that DTT does not block type I
receptor homodimerization, an event upstream of ligand induced hetero-oligomerization. In
conjunction with work of others, this would suggest that DTT blocks a step in complex
formation further downstream, presumably interactions between structural domains
involved in direct TPRI and TfRII association. The intracellular domain of TPRI appears
to contain at least one of these key structural elements as cytoplasmic truncations of TfRI
reach the cell surface, but fail to associate with a wildtype TPRII.
69
Experimental Procedures
Cell culture
Mv 1 Lu (American Type Culture Collection catalog# CCL-64) mink lung epithelial cells
were cultured in modified Eagles medium (MEM) supplemented with 10% fetal bovine
serum, 2mM glutamine, 100 units/ml of penicillin, 0.1 mg/ml streptomycin and MEM non-
essential amino acids (Life Technologies). HYB2 cells are a gift of Dr. A. Geiser (National
Institutes of Health) and were grown in Dulbecco's modified Eagle medium supplemented
as above, except for MEM non-essential amino acids.
Construction of TGF- receptor cytoplasmic truncations
HA-tagged full-length T$RI (Gilboa et al., 1998) or myc-tagged full-length TfRII (Henis
et al., 1994) were subcloned into pcDNA3.1 (Invitrogen). Cytoplasmic truncations of these
tagged receptors were constructed by polymerase chain reaction (PCR). With respect to
T$RI, primers introducing a stop codon after either cysteine 148 (using starting methionine
as 1) or histidine 358 followed by a Not I site together with a T7 primer were used to
generate PCR fragments encoding TORI truncations. The resulting DNAs were then
subcloned into the Hind III and Not I sites of pcDNA3. 1. Similarly, a primer introducing a
stop codon after serine 199 in the T3RII sequence followed by a Not I site were used
together with T7 to generate a cytoplasmically truncated TfRII receptor. The PCR fragment
was then subcloned into the EcoRI and NotI sites of pcDNA3. 1. This truncation is identical
to one characterized by (Wieser et al., 1993)
[1251] TGF- binding and cross-linking studies
After two washes with KRH buffer (50mM Hepes, pH 7.4, 8mM NaCl, 5mM MgSO4,
0.5mM CaCl2, 0.5mM KCl), confluent plates of MvlLu or HYB2 cells were incubated for
10 minutes at 37C with KRH-BSA (KRH containing 0.5% BSA). Afterwards, they were
then pre-treated with KRH-BSA or in some experiments, KRH-BSA containing a
particular compound for 10 or 15 minutes at 37*C. Cells were then placed on ice and after
four washes with KRH buffer, binding and cross-linking with [1251] TGF-31 or [1251]
TGF-$2 was then performed as described in (Cheifetz et al., 1990). Briefly, 10 7 cells were
incubated with 150 pM [1251] TGF-P1 or [1251] TGF-P2 in KRH buffer containing 1%
fatty acid free serum albumin for 2 hours on ice. Following cross-linking with 50Ogg/ml
disuccinimidyl suberate (DSS), the cells were washed three times with PBS (1 mM
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KH2PO4, 10 mlM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, pH 7.0), and lysed in TBS-
GT buffer (137 mM NaCl, 20 mM Tris-HCl [pH 8.0], 1% Triton X-100, 10% glycerol).
Immunoprecipitations
After a 5 minute centrifugation, cleared lysates were incubated with an antibody/protein-A
sepharose mixture at 4'C. Antibodies used include 12CA5 (c-HA; lgl/IP) mouse ascites
raised against an epitope of the influenza hemagglutinin (HA) protein (Wilson et al., 1984),
a monoclonal myc antibody (9E10, 3g1/IP) (Evan et al., 1984), a polyclonal anti-peptide
antibody recognizing the C-terminus of T-RII (antibody 260; 5gl/IP) (Moustakas et al.,
1993), and a polyclonal antibody raised against the cytoplasmic juxtamembrane region of
TfRI (VPN;5l/IP ). (Franzen et al., 1993). After a 2 hour incubation at 4'C,
immunoprecipitates were washed three times with TBS-GT followed by one wash with
PBS. Immunoprecipitates were separated by SDS-PAGE and exposed to a Fuji
phosphoimager screen for quantitation and analysis.
Purification of GST-Smad3
GST-Smad3 fusion proteins were produced in DH1OB E. coli harboring cDNA encoding
GST-SMAD3 subcloned into the pGEX-2T bacterial expression vector. (Zhang et al.,
1996) The method of purification was adapted from (Bitter and Roeder, 1979; Frangioni
and Neel, 1993). Cultures were grown overnight at 37'C and then diluted 1:10 into 6 liters
of Luria Broth (LB). After incubation for 4 hours at 37"C, cells were induced for 2 hours
with 1 mM isopropyl -f-D thiogalactopyranoside (IPTG) at 30'C. Bacteria were pelleted,
resuspended in 120 mls of NETN (100mM NaCl, 20mM Tris (pH 8.0), 1mM EDTA,
0.5% NP-40) with imM PMSF, and sonicated for 15 seconds, 5-6 times in an ice bath.
After clearing the lysates with a 15 minute centrifugation, fusion proteins were isolated by
incubation with 500gl of a GST-Sepharose4B 1:1 slurry (Pharmacia) for 30 minutes at
4'C. After washing the beads three times with NETN, GST-fusion proteins were eluted at
room temperature with 5mM reduced glutathione in NETN. The resulting eluate was then
dialyzed against buffer D (20mM Tris (pH 7.9), 20% glycerol, 0. IM KCl, 0.2mM EDTA,
0.5mM phenylmethylsulfonyl fluoride (PMSF), 0.5mM DTT) overnight at 4'C and then
stored at -70'C.
GST-Smad3 transphosphorylation assay
An in vitro assay for ligand induced transphosphorylation of GST-Smad3 is described in a
previous study.(Wells et al., in press) Briefly, MvlLu or transfected COS cells at ~ 50-
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80% confluence were washed three times with MEM followed by a 10 minute incubation at
37'C in MEM or MEM containing 1mM DTT or TCEP. Afterwards, cells were washed
four times with MEM and then treated with 100pM TGF-P 1 for 15 minutes at 37'C. Cells
were washed three times with pre-chilled PBS and then lysed in lysis buffer (50mM Tris
(pH 8.0), 150 mM NaCl, 1mM EDTA, 50mM NaF, 1mM NaVO3, 1% NP40, 10%
glycerol) and 1mM PMSF. 1 gg of GST-Smad3 (Zhang et al., 1996) was added to cleared
lysates and incubated for 1 hour at 4'C followed by addition of glutathione sepharose 4B
(Pharmacia; 20l of 1:1 slurry) and another 1 hour incubation at 4*C. Beads were then
washed three times with lysis buffer and once with kinase buffer (50mM Tris (pH 7.4),
10mM MgCl2, 1mM DTT). To 20l of the glutathione bead mixture, 101 of a mix
containing 1 jil loX kinase buffer, 0.4 jil of 10mM ATP, 0.5 gl y3 2 P-ATP
(6000mCi/mmol), and 8gl of H20. After a 30 minute incubation at 30'C, samples were
separated by 8% SDS-PAGE (Laemmli, 1970), transferred to 0.22 RM porosity
nitrocellulose and then exposed to Kodak XAR film.
COS cell transfections
Using the DEAE/dextran method, COS-7 cells were transiently transfected (Seed and
Aruffo, 1987) with 3 jg of human type II TGF-P receptor in the pcDNA1 vector
(Invitrogen).(Lin et al., 1992) and 10 kg of either a constitutively active TfRI mutant
(T204D) (Wieser et al., 1995) subcloned in pcDNA3.1 (Invitrogen) or wild-type TIRI in
CMV-7.(Chen and Weinberg, 1995)(Chen and Weinberg, 1995; Andersson et al., 1989)
Both type I receptors are HA-tagged at the C-terminus. In Figure 1B, the following two
cDNAs were co-transfected: 10gg's of an N-terminal Myc-tagged human type II TGF-P
receptor (Henis et al., 1994) in the pcDNA1 vector (Invitrogen) and a C-terminal HA-
tagged human type I receptor expressed in the CMV-7 vector. In Figure 4A, 3Rg of wild-
type TfRII in pcDNA1 were co-transfected with 10g of either HA-tagged full-length
TfRI, a partial cytoplasmic truncation (HA-TIRI(T358)) or a complete cytoplasmic
truncation (HA-TPRI(Tl48)) subcloned in pcDNA3.1. In Figure 4B, 3jg of wild-type
TPRI in CMV-7 were co-transfected with iOggs of either myc-tagged full-length TIRII
(myc-TPRII) in pcDNA3.1 or a cytoplasmically truncated T$RII (myc-TPRII(T932)).
Forty-eight to 72 hours after transfection, cells were then assayed for the relevant receptor
activity.
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Results
Previous studies have documented the loss of cell surface TPRI binding to TGF-P1
as a consequence of DTT pre-treatment. (Cheifetz et al., 1990; Wrana et al., 1992) In
Figure 1A, we show that in both mink lung epithelial (MvlLu) cells, and HYB2 cells (a
TGF-p-responsive line resulting from a fusion of a human EJ bladder carcinoma and an
SW480 colon carcinoma cell) (Geiser et al., 1989; Geiser et al., 1992), antisera specific for
TPRI immunoprecipitate [1251] TGF- 1 cross-linked to TPRII as well as to T1-RI (lanes 5
and 7). Similarly, antisera recognizing TfRII immunoprecipitate [1251] TGF- 1 cross-
linked to TIRI as well as to Tf-RII (lanes 1 and 3). Hence, TGF- 1 binding correlates
with formation of a stable types I and II receptor complex. Pre-treatment of either cell line
with DTT not only abrogates binding of [1251] TGF-1 to TPRI, but also blocks co-
immunoprecipitation of TfR1 with [1251] TGF-f1-bound TfRII (lanes 6 and 8). This
would suggest that in addition to abolishing ligand binding to the type I receptor, DTT also
blocks types I and II association. In contrast, [1251] TGF-P 1 binding to the type II receptor
remains intact after DTT pre-treatment (lanes 1 - 4). Similar results were observed in L6 rat
skeletal muscle myoblasts as well as when using antisera specific for the C-terminus of
TPRI. 1
To further examine how DTT affects interactions between TfRI and TPRII, we
took advantage of the distinct binding requirements of TGF-2. In contrast to TGF- 1,
TGF-P2 cannot bind to TPRII unless TSRI is co-expressed, consistent with it binding to
pre-formed types I and II receptor complexes.(Rodriguez et al., 1995) Hence, should DTT
pre-treatment compromise interactions between TPRI and TfRII, one would observe the
loss of TGF-2 binding and cross-linking to both receptor types. And indeed in transiently
transfected COS cells, DTT pre-treatment of L6 myoblasts blocks [1251] TGF-2 binding
and cross-linking to both TIRII as well as to TfRI (Figure 1B, lanes 2 and 4). Similar
results were obtained in L6 myblasts (Figure 1C).
We then screened a number of related thiol-based compounds for their ability to
block complex formation. As shown in other studies, DTT pre-treatment not only prevents
TPRI binding and cross-linking to TGF- 1, but also blocks downstream signalling as
demonstrated by its inhibition of TGF-P dependent in vitro transphosphorylation of
Smad3, a known in vivo TPRI substrate. (Figure 2A and B, lane 3).(Liu et al., 1997;
Nakao et al., 1997; Wells et al., in press; Zhang et al., 1996) More importantly, Figure
2A, lane 7 shows that among the compounds tested, only 2,3 dimercaptopropanol (2,3
DMP) similarly inhibits type I receptor binding and cross-linking, albeit with lower efficacy
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than DTT. This partial effect is consistently observed when immunoprecipitating with either
TfRI or TfRII antisera. In addition, the residual type I receptor recruitment results in a
corresponding partial loss of TGF- induced in vitro transphosphorylation of Smad3.
(Figure 2A and 2B, lane 7) Among the compounds tested, DTT and 2,3 DMP are unique in
that they are both membrane-permeable and contain dithiols. In contrast, neither a
membrane-impermeable dithiol such as diethyldithiocarbamic acid (DDC), nor monothiols
such as -mercaptoethanol or 2-mercapto-ethanesulfonic acid (MESA) exert any detectable
effect upon formation of a functional types I and II complex (Figures 2A and 2B, lanes 4-
6). These compounds all lack one or both properties shared by 2,3 DMP and DTT.
Mechanistically, it is possible that DTT and 2,3 DMP block direct interactions
between TfRI and TfRII. Alternatively, they may inhibit an upstream step necessary for
formation of a functional TfRI and TPRII heterotetramer, most notably TPRI
homodimerization.(Luo and Lodish, 1996; Weis-Garcia and Massague, 1996) Analysis of
the ability of the TPRI T204D mutant to signal with or without DTT pre-treatment would
allow us to distinguish between these two possibilities. Specifically, T204D encodes for a
constitutively active kinase that signals independently of the type II receptor; however, like
its wild-type counterpart, it still requires homodimerization to signal.(Luo and Lodish,
1996) In Figure 3 we co-transfected DNA encoding the wild-type TPRII together with
either the constitutively active T204D or wild-type TPRI and compared the resulting
patterns of in vitro Smad3 phosphorylation with or without DTT pretreatment. DTT
inhibition of type I homodimerization should manifest as the loss of Smad3
transphosphorylation by both T204D and wild-type T3RI. However, Figure 3 shows
clearly that this is not the case. Although DTT can inhibit Smad3 transphosphorylation in
cells expressing wild-type TfR1, no effect is observed in those expressing the constitutive
T204D mutant. On the other hand, like wild-type TfR1, T204D is also sensitive to DTT
pre-treatment as assayed by [1251] TGF-P1 binding and cross-linking. (Figure 3B)
Therefore, DTT exerts no deleterious effect upon homodimerization, but rather acts
elsewhere in the sequence of events leading to complex formation.
Furthermore we find that both partial and complete deletions of the TfRI
cytoplasmic domain result in truncated type I receptors that cannot bind [12 5 I]-TGFPI
suggesting that they are unable to associate with TfRII. Specifically, binding and cross-
linking of [1251] TGF- 1 were performed on COS cells co-transfected with wild-type
TPRII and either full-length or truncated versions of an HA-tagged TPRI. Both HA-TPRI
(T358) and (T148) are expressed on the surface of COS cells as determined by
immunofluorescence (data not shown). Nevertheless, as depicted in Figure 4A, antibodies
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specific for the HA epitope immunoprecipated a full-length tagged TfRI, but failed to
immunoprecipitate either truncated receptor. This is consistent with the notion that the
intracellular domain contains structural elements necessary for association with TfRII. In
contrast, a cytoplasmically truncated TPRII is indistinguishable to its full length counterpart
in that it maintains the ability to bind [1 2 51]-TGF1 and associate with TfRI in a DTT-
sensitive manner. Similar to Figure 4A, binding and cross-linking of [1251] TGF-1 was
performed on COS cells co-transfected with wild-type TfRI and either a myc-tagged full-
length TPRII or a myc-tagged T3RII truncated of its intracellular domain. With both type H
receptors, anti-sera specific for the myc epitope co-immunoprecipitates [1251] TGF- 1-
bound TPRI as depicted in Figure 4B (lanes 1 and 3). This is consistent with previous
findings demonstrating that the cytoplasmic domain of TIRII is dispensable for its
association with TIRI.(Wieser et al., 1993) Moreover, like its full-length counterpart, a
truncated T$RII recruits T$RI in a DTT-sensitive manner as DTT pretreatment blocks co-
immunoprecipitation of both a full-length and truncated T$RII with TGF- 1-bound TfRI
(Figure 4B, lanes 2 and 4).
Lastly, we note that TPRI.TfRII interactions when observed in transfected COS
cells exhibit characteristics distinct to what is observed in endogeneously expressing cell
lines. In particular, they produce distinct patterns of [12 51]-TGF-1 bound receptors. In
MvlLu, L6 1, and HYB2 cells, DTT brings about the complete loss of ligand-bound T$RI
as well as TfRII co-immunoprecipitating with TIRI. (Figures IA and 2A) However,
under the same conditions, COS cells do exhibit detectable amounts of both receptors.
(Figure 3B).
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Discussion
In this report, our findings are four-fold: 1) In contrast to TGF- 1, TGF-P2
binding to both TfRI and TfRII is disrupted by DTT pre-treatment ;2) 2,3 DMP similarly
inhibits TGF- receptor complex assembly possibly allowing identification of chemical
properties shared with DTT that correlate with the observed effects and; 3) DTT exerts no
effect upon type I receptor homodimerization; 4) The cytoplasmic domain of TPRI, but not
TfRII, is necessary for receptor complex formation.
We cannot rule out the possibility that DTT simply weakens these receptor
complexes rendering them sensitive to dissociation after detergent lysis as observed in our
immunoprecipitation studies. Nevertheless, further evidence for DTT-induced disruption of
functional TPRI-TRII interactions is provided by analysis of TGF-2 binding and cross-
linking. In light of its requirement for pre-formed types I and II complexes on the cell
surface to bind, failure to bind either receptor type would suggest that the integrity of such
pre-existing complexes becomes functionally compromised subsequent to DTT pre-
treatment and prior to detergent lysis.
However, based on a technique using antibody-mediated immunofluorescence
copatching of TGF-P receptors in live COS cells, Wells and co-workers report that ligand
induced TP-RI/RII oligomerization is not DTT sensitive.(Wells et al., in press) Hence it is
possible that DTT may not bring about complete complex dissociation. Nevertheless, their
resulting stuctural integrity is such that they are unable to function in TGF- signalling as
measured by at least three criteria: (1) it prevents TGF-31 binding to the type I receptor,
and as a consequence; (2) ligand-induced Smad3 transphosphorylation is blocked; (3)
Neither receptor type in the complex bind TGF-32. Thus, DTT compromises the complex
to the extent that it is unable to signal in response to ligand stimulation.
Furthermore, our data indicate that at least in a subset of cell-surface receptor
complexes, the nature of their interactions in COS cells is distinct from that observed in
endogeneously expressing cell lines. This would suggest that in COS cells, at least a subset
of cell-surface complexes remain intact after dithiol pretreatment and therefore possess
properties distinct from what is observed in endogenously expressing cell lines. It is
possible that overexpression may alter the oligomeric or conformational state of these
complexes and, as a consequence, alter their subsequent DTT sensitivity.
76
A previous study reports that in MvlLu cells, antisera specific for the type I
receptor immunoprecipitate [1 2 5 1]-TGF-I 1 bound type II receptor after DTT pre-
treatment.(Vivien and Wrana, 1995) Wells and co-workers propose that the discrepancy
between this and our observations could be due to the different concentrations of detergents
used during lysis.(Wells et al., in press)
Furthermore, among a number of thiol-based reducing agents tested, only 2,3 DMP
exhibits a similar inhibition of types I and II receptor association. Both 2,3 DMP and DTT
are membrane-permeable and possess dithiols. Compounds lacking one or both
characteristics exert no effect on complex formation suggesting that both properties are
somehow involved in DTT's mode of action. DTT's effects has been attributed to the
reduction of critical disulfide bonds in the extracellular domain of T$R1, altering its
conformation and ultimately preventing TGF- binding.(Vivien and Wrana, 1995)
We also show that DTT does not disrupt type I receptor homodimerization and
hence must act elsewhere in the sequence of events leading to complex formation. In light
of our data, we propose that through properties related to its dithiol group, DTT crosses the
membrane and acts upon an intracellular factor, possibly the cytoplasmic domain of either
receptor, to abolish functional TPRI-TPRII interactions. Nevertheless, it has been shown
that the type II receptor cytoplasmic domain is dispensable for complex formation.(Wieser
et al., 1993) We further report that it has no role in conferring DTT sensitivity to receptor
complex formation. On the other hand, type I receptors truncated of their intracellular
domain are expressed on the cell surface, but fail to interact with TfRII suggesting that this
cytoplasmic region of TfRI plays an essential role in TfRI.T3RII interactions. We
therefore propose that DTT does not directly affect TfRII, but instead acts upon structural
elements contained with the cytoplasmic domain of T3RI to block functional receptor
complex formation.
It is clear that additional work is required to further elucidate how DTT and other
similar agents act to inhibit functional TGF-$ receptor oligmerization. Specifically, work
focusing on the identification of domains within the TIRI cytoplasmic domain as well as
possibly other structural determinants required for their interactions would be particularly
fruitful. Through this approach, we hope to obtain further insights into the series of events
necessary for receptor complex assembly.
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Figure Legends
Figure 1: DTT blocks functional interactions between TPRI and TPRII.
A) Binding and cross-linking of [1251] TGF-P1 to MvlLu and HYB2 cells.
MvlLu cells (lanes 1, 2, 5, and 6) and HYB2 cells (lanes 3, 4, 7, and 8) were pre-
incubated with (lanes 2, 4, 6 and 8) or without 1 mM dithiothreitol (DTT) (lanes 1, 3, 5
and 7) for 15 minutes at 37 'C, and then upon washing cells 5 times with KRH buffer
subjected to [1251] TGF- 1 binding and cross-linking as described in Experimental
Procedures. After cell lysis, half of the sample was subjected to immunoprecipitation with
an anti-peptide antibody raised against the C-terminus of T$RII (antibody 260; lanes 1 - 4);
the other half was immunoprecipitated with an anti-peptide antibody specific for the
cytoplasmic juxtamembrane region of TfRI (VPN; lanes 5 - 8). The resulting
immunoprecipitates were then resolved by SDS-PAGE, dried and then exposed to a Fuji
phosphoimager screen.
B) DTT sensitivity of [1251] TGF-P2 binding to COS cells co-expressing
types I and II TGF-P receptors
COS cells co-transfected with cDNA encoding N-terminal terminally myc tagged T3RI and
C-terminal HA tagged Tf-RII. Forty eight to 72 hours after transfection, plates were
preincubated with either KRH (lanes 1 and 3) or KRH containing 1mM DTT (lanes 2 and
4) for 15 minutes at 37'C followed by binding and cross-linking to [1251] TGF-$2.
Samples were then split into two and immunoprecipitated with either an HA or myc
monoclonal antibody. The resulting immunoprecipitates were then resolved by SDS-
PAGE, dried and then exposed to a Fuji phosphoimager screen. Methods for both binding
and cross-linking, and immunoprecipitations are described in Experimental Procedures.
C) DTT sensitivity of [1251] TGF-P2 binding to L6 myoblasts.
L6 rat skeletal muscle myoblasts were pre-incubateed with or without 1mM DTT (lanes
2,4,6 and 8) for 10 minutes at 37*C, then upon washing cells 5 times with KRH buffer
subjected to [1251] TGF-2 binding and cross-linking as described in Experimental
Procedures. After cell lysis, half of the sample was subjected to immunoprecipitation with
an anti-peptide antibody raised against the C-terminus of TPRII (antibody 260; lanes 3,4,7
and 8); the other half was immunoprecipitated with an anti-peptide antibody specific for the
cytoplasmic juxtamembrane region of T3RI (VPN; lanes 1,2,5 and 6). The resulting
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immunoprecipitates were then resolved by SDS-PAGE, dried and then exposed to a Fuji
phosphoimager screen.
Figure 2: Only membrane permeable dithiols can disrupt types I and II
receptor complexes.
A. [1251] TGF-P1 binding and cross-linking to MvlLu cells after pre-
treatment with various thiol based reducing agents
MvlLu were pre-incubated in KRH-BSA or KRH-BSA containing 1mM of the following
reducing agents for 10 minutes at 37'C: dithiothreitol (DTT)(lane 3); f-mercaptoethanol
(lane 4); 2-mercaptoethane sulfonic acid (MESA) (lane 5); diethyldithiocarbamic acid
(DDC) (lane 6); 2,3 dimercaptopropanol (2,3 DMP) (lane 7). Lanes 1 and 2 remained
untreated. Cells were then washed four times with KRH and then bound and cross-linked
to [1251] TGF- 1. Cell were then lysed, split in half and then immunprecipitated with
antibodies specific for either Tf-RI or TP-RII. Immunoprecipitates were then resolved by
8% SDS-PAGE, dried and then exposed to a Fuji phosphoimager screen. Both binding and
cross-linking and immunoprecipations were performed as described in Experimental
Procedures.
B. In vitro analysis of TGF-P induced GST-Smad3 phosphorylation after
pre-treatement with various thiol based reducing agents.
MvlLu plates were grown and pre-treated as described above. Following washes with
KRH, all plates except for lane 1 were treated with 200pM TGF-P 1 for 15 minutes at
37'C. Cells were then assayed for Smad3 transphosphorylation activity as described in
Experimental Procedures.
Figure 3: T204D transphosphorylation of GST-Smad3 occurs independently
of DTT pretreatment. However, it exhibits similar DTT sensitivity to that of
the wild-type TP-RI in binding and cross-linking to [1251] TGF-p1.
A. T204D and wild-type type I TGF-P receptor transphosphorylation of
GST-Smad3 after DTT pretreatment.
COS cells were co-transfected in duplicate plates with pcDNA1 containing cDNA encoding
human TIRII and pcDNA3.1 containing cDNA encoding the constitutively active TPRI
T204D mutant or wild-type TfRI. Both type I receptors are C-terminally tagged with an
HA epitope tag.(Chen and Weinberg, 1995; Wieser et al., 1995) Forty-eight to 72 hours
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after transfection, cells were washed once with KRH and then pre-treated with KRH-BSA
or KRH-BSA containing 1mM DTT for 10 minutes at 37*C followed by four washes with
KRH. Afterwards, all plates were stimulated with 100pM TGF- 1 for 15 minutes at 37'C.
Cells were then assayed for Smad3 transphosphorylation as detailed in Experimental
Procedures.
B. Binding and cross-linking of [12511 TGF-P1 to COS cells expressing
TP-RII with either T204D or wild-type TfRI after DTT pretreatment.
COS cells were transfected and cells were pre-treated with DTT as described in Figure 3A.
Subsequent binding and cross-linking to [1251] TGF-P1 was performed and then
immunoprecipitated with an HA antibody as described in Experimental Procedures.
Figure 4: The cytoplasmic domain of TPRI is required for interactions
between TPRI and TPRII.
A. Cytoplasmic truncations of TPRI are unable to bind and cross-link
[1251] TGF-P1
COS cells were co-transfected with wildtype TfRII expressed in pcDNA1 and either
wildtype HA-tagged TPRI (HA-TRI), or a partially (HA-TfRI(T358)) or fully (HA-
T$RI(T148)) cytoplasmically truncated HA-tagged T$RI expressed in pcDNA3.1. 48-72
hours after transfection, binding and cross-linking to 400pM [1251] TGF- 1 was
performed and their subsequent lysates were immunoprecipitated with an anti-HA antibody
as described in Experimental Procedures.
B. Cytoplasmic truncation of TPRII can still bind [1251] TGF-P1 and
associate with TPRI in a DTT sensitive manner.
COS cells were co-transfected in duplicate plates with wild-type TfRI expressed in pCMV-
7 and either myc-tagged full-length T$RII (myc-TPRII) or a cytoplasmic truncation (myc-
TIRII(T932)). 48-72 hours after transfection, plates were pre-treated with KRH-BSA
(lanes 1 and 3) or KRH-BSA with lmM DTT at 37C for ten minutes. After 4 washes with
KRH, binding and cross-linking to 100pM [1251] TGF-P1 was performed and subsequent
cell lysates were immunoprecipitated with an anti-myc antibody as described in
Experimental Procedures.
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Footnotes
1 Wells, R. and Lodish, H.F., unpublished observations.
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Chapter 4
Investigation of a putative role for zinc as an essential factor for functional
TGF-P receptor complex formation
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Preface
Experiments described in Figures 1 and 3 were conducted with Dr. Carlos Rodriguez.
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Abstract
The TGF- receptor signalling complex is composed of two receptor serine/threonine
kinases: type I (TfRI) and type II (TPRII). Binding of the ligand TGF- 1 to TfRII causes
TRII to associate with and phosphorylate TfRI. These interactions are essential for TGF-
(1-activated signal transduction. Cheifetz and co-workers showed that dithiothreitol (DTT)
abolished the ability of TGF- 1 to bind TPRI, yet binding to TPRII remained
intact.(Cheifetz et al., 1990) As shown by Chapter 3 and others (Wells et al., in press),
DTT not only prevents ligand binding, but also prevents the formation of a ligand-induced
complex competent to signal. It is thought that DTT, by reducing critical disulfide bonds in
the extracellular domain of TfRI, alters the receptor's conformation, thus preventing TGF-
1 binding.(Vivien and Wrana, 1995) Only membrane-permeable dithiols exert the same
effect (Chapter 3) suggesting that an intracellular factor could be their target. Furthermore,
because DTT, like other dithiols, is also a metal chelator, we thought it possible that
chelation rather than disulfide bond reduction explained these observations. Hence, our
model predicts that a divalent metal, most likely Zn2 +, is essential for the cytoplasmic
domain of the type I receptor to assume a particular conformation necessary for interactions
with the type II receptor. In this chapter, we test this model by examining a number of
predictions it makes regarding the structural nature of the type I receptor. First, it predicts
that the type I receptor cytosolic domain should bind Zn2 + and its removal by pre-treatment
with membrane-permeable chelators should block formation of a TfRI/TfRII complex.
Furthermore, mutants of the type I receptor that cannot bind zinc should correspondingly
fail to associate with the ligand bound type II receptor and therefore would be unable to
signal. We report experimental results demonstrating that the intracellular domain of TPRI
binds zinc in vitro. However, membrane-permeable zinc chelators fail to exert any effect
upon T$RI:TPRII interactions and moreover, TPRI mutants defective in zinc binding do
not exhibit any significant defiencies in activating TGF-3 dependent PAI-1 promoter
activity. Therefore, our conclusions ultimately do not support an essential role for a
divalent metal ion, namely zinc, in TGF-P signal transduction.
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Introduction
As described in Chapter 3, membrane permeable dithiols specifically abrogate
functional recruitment of the type I TGF- receptor to the ligand bound/type II receptor
complex. In particular, DTT and 2,3 DMP prevent both [12 5 I]TGF- 1 binding and cross-
linking to the type I receptor as well as type I receptor mediated Smad3
transphosphorylation. In contrast, neither a membrane-impermeable dithiol such as
diethyldithiocarbamic acid (DDC), nor monothiols such as P-mercaptoethanol or 2-
mercapto-ethanesulfonic acid (MESA), exerted any effect. Hence, two properties appear to
be necessary for type I receptor recruitment: (1) membrane permeability and (2) the
presence of dithiols. In this chapter, we describe a model explaining the molecular
mechanism underlying the DTT effect and test several predictions it makes regarding the
structural make-up of the type I receptor.
In light of the requirements for membrane permeability, we thought it possible that
these dithiols may be affecting intracellular domain(s) of the types I and/or II receptor
cytoplasmic domain. However, it has been shown that the type II receptor cytoplasmic
domain is dispensable for ligand induced association with the type I receptor. (Wieser et
al., 1993) Since dithiols disrupt the formation of a functional types I and I complex, it
follows that the more likely target of these reagents is the type I receptor cytoplasmic
domain.
The DTT effect was first observed by Cheifetz and co-workers.(Cheifetz et al.,
1990) Vivien and co-workers attribute this effect to DTT reducing disulfide bonds in the
extracellular domain of TP-RI, rendering it unable to bind ligand.(Vivien and Wrana, 1995)
In most proteins, however, disulfide bonds are buried in the interior and are not accessible
to reducing agents in the absence of denaturation.
On the other hand, DTT , is also a potent chelator, a property distinguishing dithiols
from monothiols. This often overlooked property of DTT led us to propose that it may be
DTT's chelating rather than reducing properties that underlie this phenomenon. Zinc is the
predominant metal found in protein structural domains. In this role, zinc serves as a
template around which proteins can form defined tertiary structures. In general, energetic
considerations dictate that polypeptides be of at least 50 residues in order to form stable
tertiary domains.(Creighton, 1993) However, by using zinc as a cross-link, polypeptides
as short as 15 residues are able to fold stably. Nature has put zinc binding domains to use
in a wide diversity of functions including protein-protein, DNA, RNA and DNA/RNA
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hybrid binding. Involvement in type I receptor function would nevertheless represent a
novel role for zinc in the oligomerization of cell surface receptors.
As shown in Chapter 3, DTT does not affect type I receptor homodimerization, but
rather appears to exert an effect specifically upon interactions between the types I and II
receptor. Therefore, our model proposes that the TPRI cytoplasmic domain requires zinc
for its proper folding which in turn, may be necessary for it to be recognized and recruited
by the TGF-$ bound TPRII.
This model requires that the type I receptor cytoplasmic domain binds zinc and
moreover, its recruitment to the TGF-P bound type II receptor complex be susceptible to
inactivation by zinc chelators. In addition, mutations in the type I receptor resulting in the
loss of zinc binding should correlate with failure to interact with the ligand bound-type II
receptor and therefore an inability to signal. Our experimental conclusions are two-fold: (1)
the type I receptor binds zinc in vitro; (2) However, we fail to find evidence of zinc being
necessary for type I receptor signalling. Therefore, although we cannot completely rule-out
the possibility of the type I receptor binding zinc, ultimately our data does not support an
essential role for it in TGF- mediated signal transduction.
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Experimental Procedures
Cell lines
MvlLu and R-1B cells (Boyd and Massague, 1989) were cultured in modified Eagles
medium (MEM) supplemented with 10% fetal calf serum, 2mM glutamine, 100 units/ml of
penicillin, 0.1 mg/ml streptomycin with non-essential amino acids (NENAA).
Binding of [6 5Zn2 +] to GST fusions proteins immobilized on glutathione sepharose or
nitrocellulose
By PCR, cDNA encoding the 356 residue cytoplasmic domain of the human type I TGF-
receptor (GST-TPRIcyt) was subcloned into the Sall and Notl sites of pGEX4T-1
(Pharmacia). Using this DNA as a template, we employed the USE method (Unique Site
Elimination) to mutate histidine and cysteine residues to alanine. (Deng and Nickoloff,
1992) The selection primer used mutates an AatII site contained within the pGEX4T-1
vector to a Sac I site. All GST-TfRlcyt fusion proteins as well as GST, GST-TPRIIcyt
(Chen and Weinberg, 1995), and GST-EpoR (Wu et al., 1995) were produced in DH10B
E. Coli. following induction for 1 hour with 1 mM isopropyl-1--D thiogalactopyranoside
(IPTG) at 37'C. Proteins were purified as previously described (Smith and Johnson, 1988)
and isolated by incubation with glutathione sepharose 4B (Pharmacia# 17-0756-01).
Proteins (0.4 to 1.2 gg) immobilized on agarose were washed three times with metal
binding buffer (MBB) (100 mM Tris, pH 6.8, 50 mM NaCl, 1 mM P-mercaptoethanol)
and resuspended in 1 ml of MBB. 2.5 pCi of [6 5 ZnC12] (Dupont NEZ 109, 5 mCi/ml, 239
mCi/mg) was then added to each sample and incubated at room temperature for one hour.
The beads were washed three times in MBB and counted in a Packard Cobra model 5002
gamma counter. Samples were analyzed on a 12.5% SDS-PAGE gel (Laemmli, 1970) and
stained with Coomassie Blue for protein quantitation. All data points were collected in
duplicate.
Zinc blots were performed in a similar manner to that described in (Schiff et al., 1988).
Briefly, proteins were purified as detailed above. Approximately, 5 gg of protein was used
for each sample. Certain fusion protein samples were digested with 1 unit of thrombin
(Sigma catalog #T6634) for eight hours at room temperature. Following separation by 10%
SDS-PAGE, proteins were transferred onto a nitrocellulose membrane. Protein quantitation
was determined by Ponceau-S staining (Sigma). Proteins were partially renatured by
incubation for several hours at room temperature in TNET (20mM Tris, pH 8.0, 100mM
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NaCl, 1mM EDTA, 1% Triton X-100) and washed three times in MBB. The filter was then
incubated in MBB for 1 hour at room temperature with IjCi/ml of [6 5 ZnC12]. After
several fifteen minute washes at 4'C with MBB, the blot was exposed to Kodak XAR film.
For quantitation, the blots were exposed to a Fuji phosphoimager screen and analysed
using MacBas v2.2 software.
[1251] TGF-P1 binding and cross-linking studies
After two washes with KRH buffer (50mM Hepes, pH 7.4, 8mM NaCl, 5mM MgSO4,
0.5MM CaCl2, 0.5mM KCl), confluent plates of MvlLu or R-1B cells were incubated for
10 minutes at 37C with KRH-BSA (KRH containing 0.5% BSA). Afterwards, they were
then pretreated with KRH-BSA or in some experiments, KRH-BSA containing a particular
compound for ten minutes at 37'C. Cells were then placed on ice and after four washes
with KRH buffer, binding and cross-linking with 12 51-TGF-$1 was then performed as
described in (Cheifetz et al., 1990). Briefly, 107 cells were incubated with 150 pM [1251]
TGF-P1 in KRH buffer containing 1% fatty acid free serum albumin for 2 hours on ice.
Following cross-linking with 50 mM disuccinimidyl suberate (DSS), the cells were washed
with PBS (1 mM KH2PO4, 10 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, pH 7.0),
and lysed in lysis buffer (TBS-GT (137 mM NaCl, 20 mM Tris-HCl [pH 8.0], 1% Triton
X-100, 10% glycerol)).
Immunoprecipitations
After a 5 minute centrifugation, cleared lysates were incubated with an antibody/protein-A
sepharose mixture at 4'C. Antibodies used include a polyclonal anti-peptide antibody raised
against the C-terminus of TP-RII (antibody 260; 5gl/IP) (Moustakas et al., 1993) and a
polyclonal antibody raised against a cytoplasmic juxtamembrane region of Tf-RI
(VPN;5g1/IP ). (Franzen et al., 1993). After a 2 hour incubation at 4*C,
immunoprecipitates were washed three times with TBS-GT followed by one wash with
PBS. Immunoprecipitates were separated by SDS-PAGE and exposed to a Fuji
phosphoimager screen for quantitation and analysis.
Purification of GST-Smad3
GST-Smad3 fusion proteins were produced in DHlOB E. coli harboring the pGEX -2T-
GST-smad3 bacterial expression vector. (Zhang et al., 1996) Method of purification is
adopted from (Bitter and Roeder, 1979; Frangioni and Neel, 1993). Cultures were grown
overnight at 37C and then diluted 1:10 into 6 liters of Luria Broth (LB). After incubation
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for 4 hours at 37'C, cells were subjected to induction for 2 hours with 1 mM isopropyl -P-
D thiogalactopyranoside (IPTG) at 30'C. Bacteria were pelleted, resuspended in 120 mis of
NETN (100mM NaCl, 20mM Tris (pH 8.0), 1mM EDTA, 0.5% NP-40) with 1mM
PMSF, and sonicated for 15 seconds, 5-6 times in an ice bath. After clearing the lysates
with a 5 minute centrifugation, fusion proteins were isolated by incubation with 500g1 of a
GST-Sepharose 4B (Pharmacia) 1:1 slurry for 30 minutes at 4'C. After washing the beads
three times with NETN, GST-fusion proteins were eluted at room temperature with 5mM
reduced glutathione in NETN. The resulting eluate was then dialyzed against buffer D
(20mM Tris (pH 7.9), 20% glycerol, 0.1M KCl, 0.2mM EDTA, 0.5mM PMSF, 0.5mM
DTT) overnight at 4*C and then stored at -70'C.
GST-Smad3 transphosphorylation assay
MulLv and R-1B cells at - 50-80% confluence were washed three times with MEM
followed by a 10 minute incubation at 37'C in MEM or MEM containing 1mM DTT or
TCEP. Afterwards, cells were washed four times with MEM and then treated with 200pM
TGF-P1 for 15 minutes at 37'C. Cells were washed three times with pre-chilled PBS and
then lysed in lysis buffer (50mM Tris (pH 8.0), 150 mM NaCl, 1mM EDTA, 50mM NaF,
1mM NaVO3, 1% NP40, 10% glycerol) and 1mM phenylmethylsulfonyl fluoride (PMSF).
After a 5 minute centrifugation, cleared lysates were immunoprecipitated with 5RI of
antibody 260 and 15 gl of a one to one protein A sepharose slurry for 1 hour at 4*C as
detailed above. Immunoprecipitates were then washed three times with lysis buffer and
once with kinase buffer (50mM Tris (pH 7.4), 10mM MgCl2, 1mM DTT). To 20g1 of the
immunoprecipitate-protein A sepharose mixture, 10 l of a mix containing 1 [dl lOX kinase
buffer, 0.4 jil of 10mM ATP, 0.5 RI 732 P-ATP (6000mCi/mmol), 2gg of GST-smad3
(Zhang et al., 1996) (1gg/gl), and 6ttl of H20. After a 30 minute incubation at 30*C,
samples were separated by 8% SDS-PAGE (Laemmli, 1970), transferred to 0.22 gM
porosity nitrocellulose and then exposed to a Kodak phosphoimager screen.
Cell-free [125I] TGF-3 binding assay
10 7 MvlLu cells were lysed in 0.2 ml of 50 mM Hepes buffer, pH 7.4, containing 1%
Triton-X- 100 and 1 mM PMSF. After centrifugation to eliminate insoluble nuclear material,
supernatants were incubated with 700 pM [1251] TGF-1 for 2 hours at 4'C in the
presence or absence of the indicated chemical agent. The samples were then subjected to
crosslinking with 50 [tM disuccinimidyl suberate (DSS) for 15 minutes at 4'C. The cross-
linking reaction was stopped by adding Tris (pH 7.4) to 1 M and the samples were
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submitted to immunoprecipitation for 2 hours at 4'C with polyclonal antibodies specific
either for TfRI (Franzen et al., 1993)(panel B) or TfRII (Moustakas et al., 1993)(panel
A). The immunocomplexes were resolved by 10% SDS PAGE gel and exposed to a Fuji
phosphoimager screen.
Mutagenesis
Forward and reverse oligonucleotides mutating cytoplasmic histidines or cysteines within
the cytoplasmic domain of the human type I receptor TGF- receptor to alanine were
synthesized. Using these primers, mutations in the full length human type I TGF-3
receptor were then generated by using overlap polymerase chain reaction (PCR). The
template used was an N-terminal HA-tagged human type I receptor (Gilboa et al., 1998)
subcloned to the Hindll/NotI sites of pcDNA3.1 (Invitrogen). The bacterial T7 primer
(Invitrogen) and an anti-sense oligonucleotide encoding the last seven codons of the type I
receptor cDNA fused to a NotI restriction site served as flanking primers for the overlap
PCR reaction. Resulting PCR products were digested by HindIl and Not I and then
inserted to these sites in pcDNA3. 1.
Luciferase assay
MulLv cells (RIB) were plated in six well dishes at a density of 5 x 105 cells/well. 24
hours later, cells were transfected by Lipofectamine Plus (Life Technologies, catalog #
10964013) with lgg of p3TP-luc (Boyd and Massague, 1989) , pSV (Clontech), and
either wildtype or a particular mutant type I receptor subcloned into pcDNA3.1
(Invitrogen). 24 hours later, cells are treated in the absence or presence of 10 or 100pM
TGF- 1. 24 hours later, cells are lysed and measured for luciferase (D-luciferin from
Analytical Luminescence, catalog #1600) and P-galactosidase activities (Tropix, catalog #
ABL120RG ) in an Autolumat LB953 EG & G Wallac luminometer. All measurements of
p3TP-luc reporter activity for luciferase activity are divided by P-galactosidase activity
readings to normalize for variable transfection efficiencies.
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Results
We use two methods to show that the cytoplasmic domain of the type I receptor
binds zinc. In Figure 1, a fusion protein of glutathione-S transferase (GST) with the
cytosolic domain of the type I receptor (GST-TRIcyt) is denatured, separated by SDS-
PAGE, transferred to a nitrocellulose filter, subjected to a standard renaturation protocol,
and then incubated with 6 5Zn2 +. Both the GST-TfRIcyt fusion as well as a known zinc-
binding protein, carbonic anhydrase, bind 6 5Zn 2 + (lanes 1 and 3). Lysozyme, a protein
not known to bind zinc, is negative in this assay (lane 2). However, since GST-protein
alone binds 6 5Zn++ weakly, we cleaved GST from the fusion protein by thrombin
digestion. The isolated type I receptor cytoplasmic domain retains its ability to bind
6 5Zn++ (lane 4).
Because of the denaturation and renaturation steps used in this assay, we cannot
determine whether the native type I receptor is able to bind zinc. In another assay, we
address this issue by incubating GST-TpRIcyt and GST-TfRIIcyt immobilized on
glutathione sepharose with 6 5Zn 2 +, yielding results similar to those of Figure 1.
Importantly, over 80% of the type I receptor cytoplasmic domains immobilized on GST
beads are able to bind 6 5Zn 2 + (Table 1). Using this more quantitative assay, we
determined the affinity of the type I receptor cytoplasmic domain for 6 5Zn2 + to be between
0.5 to 1 pM (Figure 2). With the exception of Cu 2 + and Co2+, other divalent metals tested
bound with at least 10-fold lower affinity, as measured by displacement of 6 5Zn2 + bound
to GST-TfRlcyt both immobilized on glutathione sepharose and on a gel blot (data not
shown). In this assay, about half of the immobilized GST-T$RIIcyt also bound 6 5 Zn 2 +
(Table 1).
Some cell surface receptors can bind ligand after detergent solubilization of cell
membranes. (Hoang et al., 1993) Since a number of metals chelators, including
ethylenediamine tetraacetic acid (EDTA)(Richardson et al., 1994) or ethylene glycol
N,N,N'N' tetraacetic acid (EGTA) (Nishio et al., 1995) are unable to cross the plasma
membrane, we studied their effects on the ability of [1251] TGF-1 to bind to the types I
and II receptor in a cell-free extract. When added to detergent solubilized MuLv cells,
[1251] TGF-0 1 bound and could be cross-linked to both receptors. They form a
heteromeric complex since antisera to the type I receptor immunoprecipitate [1251] TGF- 1
cross-linked to the type II receptor and vice-versa. (left lanes in Figures 3A and 3B). In this
assay, several chelators, including broad specificity chelators like EDTA or BAPTA
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(Aballay et al., 1995) and relatively zinc-specific chelators such as 1,10 O-phenanthroline
(Auld, 1988; Schiavo et al., 1993) and TPEN (Auld, 1988; luliano et al., 1992)
specifically inhibit binding of [1251] TGF- 1 to the type I receptor (panel B) but exert no
effect on binding of [1251] TGF-31 to the type II receptor (panel A). DTT only partially
inhibits receptor oligomerization (panels A and B). This is consistent with its ability to only
partially remove 6 5 Zn2 + from the GST-TfRIcyt fusion protein. (Table 2B)
However, in assays using live cells, a series of repeated washings separates
chemical pre-treatment from subsequent [1251] TGF- 1 addition. In contrast, the cell-free
assay requires co-incubation of [1251] TGF- 1 with these chemical agents. As a
consequence, we cannot exclude possible changes exerted by these agents on the ligand
and its ability to form a heteromeric complex. To address this issue,we tested whether pre-
treatment of intact cells with two membrane-permeable zinc chelators (described in Chapter
2) can block subsequent [1251] TGF-1 binding and cross-linking to the type I receptor.
As shown in figures 4A and B, neither 1,10 0-phenanthroline nor TPEN have any effect,
in contrast to the results obtained in the cell-free assay.
Zinc structural domains are characterized by the almost predominant use of
histidines and cysteines as coordinating residues. The type I receptor cytoplasmic domain
contains an unusually high density of histidines (-5%) and cysteines, both of which could
participate in binding putative zinc atom(s). Indeed Figures 5A and B show that mutations
to alanine of these residues result in the loss of 6 5Zn 2 + binding. In most cases, these
mutants exhibit 40-60% binding relative to the wildtype receptor cytoplasmic domain.
We proceeded to examine the functional consequences of these mutants with respect
to their abilty to induce TGF-$-dependent activation of the PAI-I promoter.(Westerhausen
et al., 1991; Wrana et al., 1992) Specifically, we constructed similar mutations in the
context of the full length type I receptor and transiently co-transfected them with a TGF-
inducible luciferase reporter construct (p3TP-luc) containing portions of the PAI-i
promoter fused to three TPA response elements into R- 1B cells, a type I receptor defective
cell line obtained by mutagenesis of the mink lung epithelial cell line MvlLu. (Boyd and
Massague, 1989) Because R-lBs lack a functional type I receptor, we can examine the
functional activity of these mutants in the absence of endogeneous receptors. Consistent
with published studies of R-lB cells, they do not respond to TGF- unless transfected
with the type I receptor cDNA.(Figure 6) As shown in Figures 6A, B and C, virtually all of
the mutants tested qualitatively exhibit similar signalling phenotypes to the wildtype type I
receptor. An exception is TfR1-H256A which exhibits slightly lowered TGF-p-induced
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signalling relative to the wildtype type I receptor (Figure 7). However, we find little
correlation between mutations resulting in the loss of in vitro 6 5Zn 2 + binding, and their
subsequent ability in the context of the full length receptor to activate TGF-f-dependent
PAI-1 promoter activity.
Also contained within or near the transmembrane domain are three cysteines and
one histidine. These residues were mutated to either alanine or serine and analyzed for their
ability to induce PAI-I promoter activity. Again, to a first approximation, these mutants do
not exhibit any significant signalling defects. (Figure 6D).
Figures 8A and B shows that pre-treatment of MvlLu cells with a non-thiol based
reducing reagent, Tris (2-carboxyethyl) phosphine (TCEP), followed by [1251] TGF-1
binding and cross-linking recapitulates the same effects as that of pre-treatment with
membrane-permeable dithiols. Like DTT, it prevents TGF- 1 from binding/cross-linking
TfRI, yet binding to TIRII remained unaffected. (Figure 8A) More importantly, when
MvlLu cells undergo TCEP pre-treatment, a type II receptor immunoprecipitate can no
longer induce in vitro transphosphorylation of Smad3. This transphosphorylation is type I
receptor-mediated as R-1B cells in contrast exhibit no ligand-dependent Smad3
transphosphorylation. Hence, TCEP also abolishes type I receptor-mediated
transphosphorylation of Smad3, suggesting that it abrogates functional type I and II
interactions in a similar manner to that of membrane permeable dithiols.
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Discussion
Two observations form the basis of the hypothesis that zinc constitutes an essential
factor for functional interactions between the types I and II TGF- receptors. First, among
the classes of thiol-based reducing agents tested in Chapter 3, only membrane permeable
dithiols abrogate recruitment of type I receptor to the ligand bound/type II receptor
complex. This would suggest that properties relating to both membrane permeability and
dithiols are necessary to elicit this effect. Metal chelation is one property that distinguishes
dithiols from monothiols. Hence, our data would be consistent with the notion that DTT
affects a cytoplasmically localized factor and by chelating a metal, most likely zinc,
prevents formation of a functional types I and II complex. Second, as shown by Wieser
and co-workers, the type II receptor cytoplasmic domain is dispensable for ligand-induced
association between the types I and II receptor. Together with this observation, the type I
receptor cytoplasmic domain would be the more likely target of these compounds. Hence
our model proposes that zinc binds to the type I receptor and is required for their functional
recruitment to the ligand bound/type II receptor complex.
Our evaluation of this hypothesis rests on four major findings: (1) when bacterially
expressed, the type I receptor cytosolic domain can bind zinc in vitro with an affinity of
lgM.(2) In a cell-free assay, Zn2 + chelators can block type I receptor binding and cross-
linking to TGF- 1. However, this assay cannot exclude the possibility that these chemical
agents adversely affect in some manner a ligand's ability to form a types I and II hetero-
complex. Furthermore, with membrane permeable zinc chelators, we fail to obtain similar
results in intact cells suggesting that these results should be interpreted with caution. (3)
Histidine and cysteine TGF-P type I receptor mutants can interact with the type II receptor
to form a complex competent to signal TGF-p-dependent PAI-l promoter activity.
Therefore, at least when mutated individually, histidine and cysteine residues are not
essential for types I and II interactions. Some mutants however do activate the reporter
construct at weaker levels relative to the wildtype type I receptor, particularly at lower
TGF-$ concentrations. This could reflect lower efficiency of folding in the endoplasmic
reticulum and consequently fewer surface receptors. However, the involvement of zinc is
unclear as our data lacks any obvious correlations between impaired signalling and loss of
in vitro 6 5 Zn 2 + binding. (4) Type I receptor recruitment can also be blocked by pre-
treatment with TCEP which to our knowledge does not possess any significant zinc
chelating properties.
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In summary, our findings suggest that in vitro , the type I receptor indeed does bind
zinc. However, there is little or no correlation between our in vitro Zn2 + binding data and
the signalling ability of full length receptors mutated in the corresponding cysteine or
histidine residues. Moreover, TCEP, which to our knowledge is a reagent that does not
chelate zinc, can recapitulate the same effects exerted by DTT, raising the question whether
the previously asserted dithiol requirement is indeed related to zinc chelation. Hence, while
we cannot rule out the possibility that the type I receptor binds zinc, our data do not support
an essential role for it in the formation of a functional types I and II TGF- receptor
complex.
The FK506 family of immunosuppressants represent another class of compounds
known to affect TPRI/RII interactions. (Chen et al., 1997; Wang et al., 1994; Wang et al.,
1996) Wang and co-workers demonstrated that the immunophilin FKBP12 binds the TPRI
GS domain preventing transphosphorylation by the type II receptor. Upon ligand-induced
TfRI/TfRII association, it is then thought that FKBP12 dissociates from TfRI.
Pretreatment of cells with immunosuppressants such as FK506 or rapamycin also cause
FKBP12 dissociation and as a result, induce elevated basal TGF-P signalling activity. It is
possible that DTT may act to stabilize FKBP12 binding to the type I receptor and
consequently prevent functional interactions between the types I and II receptor.
Nevertheless, reinterpretation of the data available to date is clearly required. We
believe that an investigation of what structural determinants of the type I receptor are
affected by DTT would be fruitful. Details of future research directions is discussed in the
proceeding chapter.
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Figure Legends
Figure 1: The cytoplasmic domain of T3-R1 binds [6 5 Zn 2 +] in an in situ
assay.
5 gg of protein are contained within each lane. Carbonic anhydrase serves as a positive
control for 6 5Zn 2 + binding (lanes 1 and 5) and lysozyme serves as a negative control
(lanes 2 and 6). In lanes 4 and 8, GST-TP-RIcyt fusion protein was digested with 1 U
thrombin as detailed in the Materials and Methods section. Following separation by 10%
SDS-PAGE, proteins were blotted onto a nitrocellulose membrane. The blot was stained
with Ponceau-red for protein quantitation as shown in Panel A. Proteins on the blot were
then partially renatured by incubation for several hours at room temperature in TNET (20
mMV Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 1% Triton X- 100) and washed three times
in MBB (see Table 1). The filter was then incubated in MBB for 1 hour at 20'C with 1
mCi/ ml of [6 5 ZnC12]. After several 15 minute washes at 4'C with MBB, the blot was
exposed to Kodak XAR film (Panel B). For quantitation, the blots were exposed to a Fuji
phosphoimager screen and the amount of radioactivity analyzed using MacBas v2.2
software.
Table 1: Binding of [6 5 Zn 2 +] to GST fusion proteins immobilized on
glutathione sepharose
Fusion proteins (0.4 to 1.2 gg) immobilized on glutathione sepharose 4B were incubated
with 2.5 gCi of [6 5 Zn2 +] in 1 ml of MBB as detailed in Experimental Procedures.
Table 2: Binding of [6 5 Zn 2 +] to GST-TP-RIcyt
Zinc binding was conducted in a manner similar to that detailed in Experimental Procedures
except in the presence of 300 gM salts (A). In (B), following incubation of GST-T3-RIcyt
beads with [6 5Zn++] and washing with MBB, samples were further incubated for 20
minutes at 20'C with the indicated concentration of each chelator dissolved in MBB.
Samples were again washed three times in MBB and quantitated in a gamma counter.
Figure 2: Affinity of GST-T-Rlcyt for [6 5 Zn 2 +]
Zn 2 + binding was conducted as detailed in Experimental Procedures, except reactions
contained increasing concentrations of unlabeled ZnCl2.
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Figure 3: Metal chelators block interactions between the types I and II
TGF-P receptors in a cell-free [1251] TGF-P1 binding and cross-linking
assay.
In a cell-free assay, detergent solubilized MvlLu cells were incubated in the presence of
[1251] TGF- 1 or [1251] TGF- 1 with 2 mM dithiothreitol (DTT), 25 mM
ethylenediamine tetraacetic acid (EDTA), 25 mM ethylene glycol N,N,N',N', tetraacetic
acid (EGTA), 2 mM 1,1 0-Phenanthroline (OP), 2 mM N,N,N',N'-tetrakis (2-
pyridylmethyl) ethylenediamine (TPEN), 5 mM 2-mercaptoethanol or 2 mM 1,2-bis-(o-
aminophenoxy) ethane-N,N,N',N'-tetraacetic acid (BAPTA). Upon completing binding
and cross-linking reactions, lysates were split into samples and the immunoprecipitated
with antibodies specific for either the types I or II receptor. Upon washing with lysis
buffer, these immunoprecipitates were resolved by 10% SDS-PAGE and exposed to a Fuji
phosphoimager screen.
Figure 4: Membrane permeable zinc chelators fail to block interactions
between the types I and II receptor in intact cells.
MvlLu or R-1B cells were pretreated with either KRH-BSA or KRH-BSA with 5 mM
1,10 0-phenanthroline, 1,7 phenanthroline, or TPEN for 10 minutes at 37'C. Cell were
then placed on ice and washed four times with pre-chilled KRH. Binding and cross-linking
with 100pM [1251] TGF-P1 was then performed as described in Experimental Procedures.
Figure 5: Mutations to alanine of cysteine and histidine residues contained
within the type I receptor cytoplasmic domain exhibit partial loss of
[6 5 Zn 2 +] binding.
A) Cysteine to alanine mutations introduced in the type I receptor
cytoplasmic domain result in partial loss of [6 5 Zn 2 +] binding.
Mutations are analyzed within the context of the GST-Tf-Rlcyt fusion protein.
Approximately 1 gg of GST-TP-Rlcyt fusion protein or GST alone was incubated with
[6 5 Zn2 +] as described in Experimental Procedures. Binding of [6 5 Zn2 +] by mutant fusion
proteins was calculated relative to wildtype GST-TJ-Rlcyt and normalized to -per mole of
protein.
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B) Histidine to alanine mutations introduced in the type I receptor
cytoplasmic domain result in partial loss of [6 5 Zn 2 +] binding.
Binding of [6 5 Zn2 +] to GST-Tf-Rlcyt histidine to alanine mutant fusion proteins was
conducted in the same manner as described above.
Figure 6: Histidine and cysteine TGF-3 type I receptor mutants can interact
with the type II receptor to form a complex competent to signal TGF-P
dependent PAI-1 promoter activity.
A) Histidine to alanine full length type I TGF-P receptor mutants activate
PAI-i promoter activity.
R-lB cells were transfected with the histidine to alanine mutants of the full length type I
receptor, the TGF- inducible p3TP-luc reporter construct and pSV3, as a control for
transfection efficiency. Data reflects the normalized luciferase activity of cell lysates after 24
stimulation at the given TGF-P concentrations.
B,C) Cysteine to alanine full length type I TGF-P receptor mutants activate
PAI-1 promoter activity.
Cysteine to alanine full length type I TGF- receptor mutants were tested in the same
manner as above.
D) Tf-R1-H256A exhibits impaired signalling relative to the wildtype type
I receptor.
Transfected into R-lB cells in the same manner as described above, T$-Rl-H256A and
wildtype I receptor were assayed for their signalling activity at various concentrations of
TGF- P1.
Figure 7: Cysteines and histidines that lie in the transmembrane signal are
not necessary for TGF- dependent PAI-1 promoter activity.
Histidines and cysteines within or neighboring the transmembrane domain of the type I
were singly mutated to either serine or alanine and by the assay outlined in Experimental
Procedures, tested for their ability to activate TGF-P dependent PAI-1 promoter activity.
Figure 8: Pre-treatment with TCEP blocks formation of a functional
TGF 1/types I and II receptor complex.
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A. TCEP blocks type I receptor binding and cross-linking to [1251] TGF-
$1
MvlLu and R-1B cells were pretreated with KRH-BSA or KRH-BSA containing 1mM
DTT or 1mM TCEP for ten minutes at 37*C and then rinsed four times with prechilled
KRH. Then as detailed in Experimental Procedures, cells were bound and cross-linked to
100pM [1251] TGF-$ 1, immunoprecipitated with both types I and II receptor antisera, and
then resolved by 8% SDS-PAGE. The gel was then dried and exposed to a Fuji
phosphoimaging plate.
B. TCEP preatment blocks TGF-0 induced type I receptor mediated Smad3
transphosphorylation.
50-80% confluent MvlLu and R-1B cells were washed with MEM two times and then
pretreated with MEM or MEM containing 1mM DTT or 1mM TCEP for ten minutes at
37'C. Plates were subsequently washed with MEM four times followed by stimulation
with 200pM TGF-P 1 for 15 minutes at 37'C. Then as described in Experimental
Procedures, the lysates of treated cells were assayed for GST-Smad3 transphorylation. R-
1B cells serve as a negative control to verify that Smad3 transphosphorylation requires the
presence of the type I receptor.
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Table 1 Binding [65ZnI to GST fusion proteins immobilized on glutathione agarose
Protein: gg protein bound to picomoles moles [65Zn] bound
column [65Zn] bound moles protein
GST 0.4 0.065 0.004
GST-TPRIcyt 1.2 10 0.84
GST-TPRIIcyt 0.8 4.84 0.42
GST-EpoR 0.75 0.089 0.006
Table 2 Binding of [65Zn] to GST-TpRI-cyt immobilized on glutathione- agarose
beads
A) In the presence of 300gM metal salts
Relative amount of [65Zn] bound + SD
no addition 1.00
CaCl2 0.90 +0.21
ZnCl2 0.018 + 0.006
CoCl2 0.51 +0.03
CuCl2 0.62 + 0.078
FeCl2 1.10 +0.15
MgCl2 0.98 +0.034
B) In the presence of chelators
Relative amount of [65Zn] bound + SD
no addition 1.00
2mM DTT 0.424 + 0.042
25mM EDTA 0.067 + 0.018
1mM O-phenanthroline 0.078 + 0.011
1mM TPEN 0.048 + 0.003
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CD4/CD8 interactions with p5 6 1ck
With respect to p5 6 1ck, zinc confers to CD4 and CD8x the ability to specifically
"fish out" one particular downstream effector among multiple Src kinases expressed within
the intracellular milieu. As a result, p561ck is placed within immediate proximity of the
TCR and other downstream substrates relevant to T-cell activation.
Possible lines of future research would center around structural characterization of
the interface between CD4/CD8x and p561ck. Crystallographic or NMR data would
provide the first picture at atomic resolution of how zinc bridges two intracellular proteins
together. Both Tat and CD4/CD8x possess zinc coordinating cysteines similar in spacing
and possessing adjacent sequences similar to those of metallothionein. Therefore, whether
the structure of the zinc-coordinating sites are at all similar may have implications to how
such structures evolved to play a role in mediating protein/protein interactions.
Furthermore, with respect to the Tat homodimer, zinc binding appears to exert structural
changes limited to the cysteine rich region of each monomer and do not appear to affect
global folding.[Frankel, 1988 #434; Frankel, 1988 #433} Biophysical measurements could
determine whether this is also the case for CD4/CD8x and p561ck. Given more structural
information, it may also be possible to identify mutations that either strengthen or weaken
the affinity of binding. Whether this could be correlated to any functional consequences in
T-cell activation may be informative.
Previous studies have demonstrated that when fused to another protein, a 6 amino
acid segment of the CD4 cytoplasmic tail is sufficient to confer association with p561ck.
(Shaw et al., 1990) Conversely, a 34 residue region at the N-terminal domain of p561ck
was sufficient to specify interactions with CD4. (Shaw et al., 1989) From a protein
engineering standpoint, inserting such sequences to proteins as tags to create de novo
metal-linked dimers may be feasible.
Aside from structural issues, one of the most challenging problems may be
determining how zinc is introduced into the CD4/p561ck dimer. Previous studies suggest
that CD4/p561ck exit the endoplasmic reticulum as a dimer. An in vitro biochemical system
in which one can examine the translation of both proteins in the presence of membranes
should enable us to determine whether the presence of zinc and other factors are necessary
to reconstitute metal-dependent association. Such studies may shed light towards the
longstanding question of how zinc and other metals are incorporated into proteins.
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TGF-P receptor complex formation
In many respects, details describing the sequence of events leading from ligand
binding to final TGF- receptor complex assembly and activation remain largely
uncharacterized. I believe that the identification of domains in both receptors necessary for
their mutual association would provide a starting point towards achieving this aim. The
type II receptor cytoplasmic domain has already been demonstrated to be dispensable for
ligand induced recruitment of the type I receptor. (Wieser et al., 1993) However, as
described in Appendix I, a type I receptor truncated of the cytoplasmic domain is expressed
on the cell surface, but cannot detectably bind and cross-link TGF- 1. Together with
previous studies demonstrating that both types I and II receptor form homodimers in the
ER (Gilboa et al., 1998), this would suggest that the type I cytoplasmic domain is not
essential for receptor homodimerization, but rather plays a role in functional association
with the ligand bound/type II receptor. Determination of whether the truncation in the
presence of the full-length type I receptor can complex with the type II receptor would be
informative.
It is possible that the TfRI cytoplasmic domain is involved in maintaining a specific
orientation of the homodimer necessary for it to be recognized by and associate with the
type II receptor. A relationship between the cytosolic domain of a receptor and extracellular
ligand binding has been previously linked to the efficiency of erythropoietin (Epo) mediated
signalling. (Livnah et al., 1996; Syed et al., 1998) In particular, Epo-mimetic ligands that
alter the orientation of the Epo receptor's extracellular region exert profound effects upon
the signalling potency of their corresponding intracellular domains. It is possible that the
type I receptor cytoplasmic domain conversely alters the conformation of the
transmembrane and/or extracellular domain allowing the receptor to assume an appropriate
orientation for functional interactions with the ligand bound type II receptor. Again,
structural data of each receptor's extracellular domain would enable us to make predictions
regarding the orientation and conformation of individual components within the TGF-P
receptor complex.
With respect to recruitment of the type I receptor to the ligand bound/type II
receptor, we cannot absolutely rule out the possibility of zinc binding the type I receptor.
Nevertheless forthcoming crystallographic data of the type I cytoplasmic domain should
unambiguously establish the presence or absence of any putative metal binding sites.
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Although p5 6 1ck binding to CD4/CD8t and association between the types I and II
TGF-P receptors appear to reflect disparate phenomena, they do however exemplify an
approach nature commonly brings to bear towards achieving highly specific and avid
protein/protein interactions. Enlisted as molecular "third parties", zinc and TGF-
essentially serve to bridge and consequently stabilize complex formation between two
proteins. As molecular details are elucidated from the study of these and other examples,
"important principles (will) emerge that explain the need for complexity of the overall
system and the unique requirements of individual proteins." (Yuk, M.H., Thesis 1995)
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